1
|
Vitale E, Bizzoca D, Di Dio F, Moretti A, Moretti B. The gender role in the publishing of Authorships in high-impact orthopedic journals. Musculoskelet Surg 2024:10.1007/s12306-023-00810-0. [PMID: 38265562 DOI: 10.1007/s12306-023-00810-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 12/27/2023] [Indexed: 01/25/2024]
Abstract
To evidence the existence of a gender gap in the orthopedic scientific literature by including also differences between some specific orthopedic surgery specialities, such as hands and feet. Then, we also considered gender role in the Authorship linked with the economic wealth of each country belonging to each Author. The gender of the first Authors of journals on orthopedics and sports medicine indexing in the Scopus database with the highest impact factor (IF) related to the year 2019, for the period from January 1, 2015, to December 31, 2020, were considered. A total of 11 journals were considered, including a total of 5474 articles, 1087 (19.86%) had a woman as the first Author and 4387 (80.14%) a man. During the studied period, the trend seems to be the same (p = 0.906): Men were significantly more producing than women in the orthopedic field both by considering the topic of the journal (p = .003), all the most impacted orthopedic journals (p < 0.001) and economies (p < 0.001). There was therefore a strong significance: In the orthopedic field, there were significantly more male researchers who presented their first name in scientific publications compared to females in all orthopedic subspecialties. The economically poorer countries published less and the role of women became almost absent.
Collapse
Affiliation(s)
- E Vitale
- Mental Health Center Modugno (Bari), Local Health Authority Bari, Bari, Italy.
| | - D Bizzoca
- Orthopaedic and Trauma Unit, Department of Basic Medical Sciences, Neuroscience and Sense Organs, School of Medicine, University of Bari "Aldo Moro", AOU Consorziale "Policlinico", Bari, Italy
| | - F Di Dio
- Student Masterr's Degree in Nursing and Midwifery, University of Bari Aldo Moro, Bari, Italy
| | - A Moretti
- Italian Group for Health and Gender, Bari, Italy
| | - B Moretti
- Orthopaedic and Trauma Unit, Department of Basic Medical Sciences, Neuroscience and Sense Organs, School of Medicine, University of Bari "Aldo Moro", AOU Consorziale "Policlinico", Bari, Italy
| |
Collapse
|
2
|
Tonelli R, Castaniere I, Cortegiani A, Tabbì L, Fantini R, Andrisani D, Gozzi F, Moretti A, Bruzzi G, Manicardi L, Cerbone C, Nani C, Biagioni E, Cerri S, Samarelli V, Busani S, Girardis M, Marchioni A, Clini E. Inspiratory Effort and Respiratory Mechanics in Patients with Acute Exacerbation of Idiopathic Pulmonary fibrosis: A Preliminary Matched Control Study. Pulmonology 2023; 29:469-477. [PMID: 36180352 DOI: 10.1016/j.pulmoe.2022.08.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Revised: 08/03/2022] [Accepted: 08/04/2022] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND Patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) may experience severe acute respiratory failure, even requiring ventilatory assistance. Physiological data on lung mechanics during these events are lacking. METHODS Patients with AE-IPF admitted to Respiratory Intensive Care Unit to receive non-invasive ventilation (NIV) were retrospectively analyzed. Esophageal pressure swing (ΔPes) and respiratory mechanics before and after 2 hours of NIV were collected as primary outcome. The correlation between positive end-expiratory pressure (PEEP) levels and changes of in dynamic compliance (dynCRS) and PaO2/FiO2 ratio was assessed. Further, an exploratory comparison with a historical cohort of ARDS patients matched 1:1 by age, sequential organ failure assessment score, body mass index and PaO2/FiO2 level was performed. RESULTS At baseline, AE-IPF patients presented a high respiratory drive activation with ΔPes = 27 (21-34) cmH2O, respiratory rate (RR) = 34 (30-39) bpm and minute ventilation (VE) = 21 (20-26) L/min. Two hours after NIV application, ΔPes, RR and VE values showed a significant reduction (16 [14-24] cmH2O, p<0.0001, 27 [25-30] bpm, p=0.001, and 18 [17-20] L/min, p=0.003, respectively) while no significant change was found in dynamic transpulmonary pressure, expiratory tidal volume (Vte), dynCRS and dynamic mechanical power. PEEP levels negatively correlated with PaO2/FiO2 ratio and dynCRS (r=-0.67, p=0.03 and r=-0.27, p=0.4, respectively). When compared to AE-IPF, ARDS patients presented lower baseline ΔPes, RR, VE and dynamic mechanical power. Differently from AE-IPF, in ARDS both Vte and dynCRS increased significantly following NIV (p=0.01 and p=0.004 respectively) with PEEP levels directly associated with PaO2/FiO2 ratio and dynCRS (r=0.24, p=0.5 and r=0.65, p=0.04, respectively). CONCLUSIONS In this study, patients with AE-IPF showed a high inspiratory effort, whose intensity was reduced by NIV application without a significant improvement in respiratory mechanics. In an exploratory analysis, AE-IPF patients showed a different mechanical behavior under spontaneous unassisted and assisted breathing compared with ARDS patients of similar severity.
Collapse
Affiliation(s)
- R Tonelli
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - I Castaniere
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - A Cortegiani
- Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy; Department of Anesthesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Italy
| | - L Tabbì
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy
| | - R Fantini
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy
| | - D Andrisani
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - F Gozzi
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - A Moretti
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - G Bruzzi
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - L Manicardi
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - C Cerbone
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy
| | - C Nani
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy
| | - E Biagioni
- Intensive Care Unit, University Hospital of Modena, Italy
| | - S Cerri
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - V Samarelli
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - S Busani
- Intensive Care Unit, University Hospital of Modena, Italy
| | - M Girardis
- Intensive Care Unit, University Hospital of Modena, Italy
| | - A Marchioni
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy.
| | - E Clini
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| |
Collapse
|
3
|
Bonavolontà V, Cianferotti L, Iolascon G, Moretti A, Brandi ML, Fischetti F, Lenzi A, Baldari C, Migliaccio S. Which physical activity in patients affected by hypoparathyroidism? A review of the literature and practical recommendations. J Endocrinol Invest 2022; 45:1289-1295. [PMID: 35122630 DOI: 10.1007/s40618-022-01756-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Accepted: 01/28/2022] [Indexed: 02/08/2023]
Abstract
BACKGROUND Hypoparathyroidism (HypoP) is a rare endocrine condition characterized by hypocalcaemia and hyperphosphatemia, as a consequence of absent or improperly low parathyroid hormone (PTH) levels. Patients affected by HypoP have a clinical condition often characterized by paresthesias and muscle spasms, as well as long-term consequences as nephrolithiasis, extraskeletal calcification, and fractures. In the literature, likely due to these symptoms, few data exist regarding the appropriate physical activity (PA) in subjects suffering from HypoP. PURPOSE This review evaluates the literature on exercise-based approaches to the management of individuals affected by HypoP and evaluates: (1) the effects of physical exercise on muscle cramps and other clinical symptoms; (2) the effects of exercise on PTH and calcium level; (3) the most suitable clinical exercise testing; and (4) the most suitable exercise combination. METHODS AND RESULTS A systematic search was conducted using the databases MEDLINE, Google Scholar using "hypoparathyroidism AND Physical Activity", "Training AND hypoparathyroidism", "Exercise AND muscle cramps", "Exercise AND Fatigue" as keywords. In addition, references list from the included articles were searched and cross-checked to identify any further potentially eligible studies. A total of 50 manuscripts were found among which 39 manuscripts were selected. A few clinical studies have been performed in HypoP patients to evaluate PA training protocols. CONCLUSION Although further research is needed to draw solid conclusions regarding best PA protocols in subjects affected by HypoP, a PA protocol has been proposed within the manuscript to encourage patients to attempt exercise to improve their clinical conditions and their quality of life.
Collapse
Affiliation(s)
- V Bonavolontà
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - L Cianferotti
- Bone Metabolic Diseases Unit, Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Firenze, Italy
| | - G Iolascon
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Napoli, Italy
| | - A Moretti
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Napoli, Italy
| | | | - F Fischetti
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - A Lenzi
- Department of Experimental Medicine, Sapienza University of Roma, Roma, Italy
| | - C Baldari
- Department of Theoretical and Applied Sciences, eCampus University, Roma, Italy
| | - S Migliaccio
- Department of Movement, Human and Health Sciences, University Foro Italico of Roma, Piazza Lauro De Bosis 6, 00195, Roma, Italy.
| |
Collapse
|
4
|
Kagot V, De Boevre M, De Saeger S, Moretti A, Mwamuye M, Okoth S. Incidence of toxigenic Aspergillus and Fusarium species occurring in maize kernels from Kenyan households. WORLD MYCOTOXIN J 2022. [DOI: 10.3920/wmj2021.2748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Aspergillus and Fusarium are fungal genera that include toxigenic and pathogenic species, able to suffuse farmers’ crops and secrete an array of small molecular weight secondary metabolites which can cause health complications to humans and animals when ingested. In sub-Sahara Africa, contamination and persistence of these fungi is increased by the tropical climatic conditions which are ideal for the fungi to thrive. This study evaluated the incidence, regional distribution and toxigenic potential of Aspergillus and Fusarium species occurring in maize kernels from Eastern, Western, Coastal and the Lake Victoria agro-ecological zones of Kenya. Maize kernels were collected from 16 households in each agro-ecological zone. Single spore technique was used to isolate pure cultures of Aspergillus and Fusarium which were identified morphologically. Further, molecular analysis was done using the internal transcribed spacer 1 (ITS 1) region of the ribosomal DNA for Aspergillus and the translation elongation factor-1 alpha (TEF-1α) for Fusarium. The potential of the isolated fungi to produce mycotoxins was probed by polymerase chain reaction (PCR) based on the aflatoxin regulatory aflaR gene in Aspergillus, and the fumonisin backbone structure gene FUM1 in Fusarium. Among the potentially aflatoxigenic A. flavus species isolated, 55% were from Eastern, 27% from the Coastal zone, 13% from Lake Victoria zone and 5% from Western Kenya. Among the potentially fumonisin producing F. verticillioides isolated, 45% were from the Lake Victoria agro-ecological zone, 30% were from Western, 15% from Eastern Kenya and 10% from the Coastal agro-ecological zone. This study adds data on potential mycotoxin hotspots in Kenya useful in employing targeted and regional mycotoxin mitigation strategies in efforts to avert future mycotoxicoses outbreaks in Kenya.
Collapse
Affiliation(s)
- V. Kagot
- Centre of Excellence in Mycotoxicology & Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
- School of Biological Sciences-University of Nairobi, Riverside Drive, 00100 Nairobi, Kenya
| | - M. De Boevre
- Centre of Excellence in Mycotoxicology & Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
| | - S. De Saeger
- Centre of Excellence in Mycotoxicology & Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
- Department of Biotechnology and Food Technology, Faculty of Science, University of Johannesburg, Doornfontein Campus, P.O. Box 17011, Gauteng, 2028 Johannesburg, South Africa
| | - A. Moretti
- Institute of Sciences of Food Production, CNR, Via Amendola 122/o, 70126 Bari, Italy
| | - M. Mwamuye
- Institute of Parasitology and Tropical Veterinary Medicine, Freie Universität, Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany
| | - S. Okoth
- School of Biological Sciences-University of Nairobi, Riverside Drive, 00100 Nairobi, Kenya
| |
Collapse
|
5
|
Chekali S, Ouji A, Somma S, Masiello M, Douihech W, Khemir E, Moretti A, Gargouri S. First Report of Wilt on Lentil ( Lens culinaris) Caused by Fusarium redolens in Tunisia. Plant Dis 2022; 106:1302. [PMID: 34661449 DOI: 10.1094/pdis-08-21-1782-pdn] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Affiliation(s)
- S Chekali
- Pôle Régional de Recherche-Développement Agricole du Nord-Ouest Semi-Aride au Kef, BP 221, 7100, Institut National de la Recherche Agronomique de Tunisie, 2049, Ariana, Tunisia
- Laboratoire de Protecion des Végétaux, Institut National de la Recherche Agronomique de Tunisie, 2049, Ariana, Tunisia
| | - A Ouji
- Pôle Régional de Recherche-Développement Agricole du Nord-Ouest Semi-Aride au Kef, BP 221, 7100, Institut National de la Recherche Agronomique de Tunisie, 2049, Ariana, Tunisia
- Laboratoire des grandes cultures, Institut National de la Recherche Agronomique de Tunisie, 2049, Ariana, Tunisia
| | - S Somma
- Research National Council of Italy, Institute of Sciences of Food Production, CNR-ISPA, Bari, Italy
| | - M Masiello
- Research National Council of Italy, Institute of Sciences of Food Production, CNR-ISPA, Bari, Italy
| | - W Douihech
- Pôle Régional de Recherche-Développement Agricole du Nord-Ouest Semi-Aride au Kef, BP 221, 7100, Institut National de la Recherche Agronomique de Tunisie, 2049, Ariana, Tunisia
| | - E Khemir
- Laboratoire de Protecion des Végétaux, Institut National de la Recherche Agronomique de Tunisie, 2049, Ariana, Tunisia
| | - A Moretti
- Research National Council of Italy, Institute of Sciences of Food Production, CNR-ISPA, Bari, Italy
| | - S Gargouri
- Laboratoire de Protecion des Végétaux, Institut National de la Recherche Agronomique de Tunisie, 2049, Ariana, Tunisia
| |
Collapse
|
6
|
Li J, Garavaglia S, Ye Z, Moretti A, Belyaeva OV, Beiser A, Ibrahim M, Wilk A, McClellan S, Klyuyeva AV, Goggans KR, Kedishvili NY, Salter EA, Wierzbicki A, Migaud ME, Mullett SJ, Yates NA, Camacho CJ, Rizzi M, Sobol RW. A specific inhibitor of ALDH1A3 regulates retinoic acid biosynthesis in glioma stem cells. Commun Biol 2021; 4:1420. [PMID: 34934174 PMCID: PMC8692581 DOI: 10.1038/s42003-021-02949-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Accepted: 12/07/2021] [Indexed: 01/31/2023] Open
Abstract
Elevated aldehyde dehydrogenase (ALDH) activity correlates with poor outcome for many solid tumors as ALDHs may regulate cell proliferation and chemoresistance of cancer stem cells (CSCs). Accordingly, potent, and selective inhibitors of key ALDH enzymes may represent a novel CSC-directed treatment paradigm for ALDH+ cancer types. Of the many ALDH isoforms, we and others have implicated the elevated expression of ALDH1A3 in mesenchymal glioma stem cells (MES GSCs) as a target for the development of novel therapeutics. To this end, our structure of human ALDH1A3 combined with in silico modeling identifies a selective, active-site inhibitor of ALDH1A3. The lead compound, MCI-INI-3, is a selective competitive inhibitor of human ALDH1A3 and shows poor inhibitory effect on the structurally related isoform ALDH1A1. Mass spectrometry-based cellular thermal shift analysis reveals that ALDH1A3 is the primary binding protein for MCI-INI-3 in MES GSC lysates. The inhibitory effect of MCI-INI-3 on retinoic acid biosynthesis is comparable with that of ALDH1A3 knockout, suggesting that effective inhibition of ALDH1A3 is achieved with MCI-INI-3. Further development is warranted to characterize the role of ALDH1A3 and retinoic acid biosynthesis in glioma stem cell growth and differentiation.
Collapse
Affiliation(s)
- Jianfeng Li
- Mitchell Cancer Institute, University of South Alabama, Mobile, AL, 36604, USA
- Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL, 36604, USA
| | - Silvia Garavaglia
- Department of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy
| | - Zhaofeng Ye
- Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, 15261, USA
- School of Medicine, Tsinghua University, Beijing, China
| | - Andrea Moretti
- Department of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy
- Structural Plant Biology Laboratory, Department of Botany and Plant Biology, University of Geneva, 1211, Geneva, Switzerland
| | - Olga V Belyaeva
- Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Schools of Medicine and Dentistry, 720 20th Street South, Kaul 440B, Birmingham, AL, 35294, USA
| | - Alison Beiser
- Mitchell Cancer Institute, University of South Alabama, Mobile, AL, 36604, USA
- Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL, 36604, USA
| | - Md Ibrahim
- Mitchell Cancer Institute, University of South Alabama, Mobile, AL, 36604, USA
- Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL, 36604, USA
| | - Anna Wilk
- Mitchell Cancer Institute, University of South Alabama, Mobile, AL, 36604, USA
- Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL, 36604, USA
| | - Steve McClellan
- Mitchell Cancer Institute, University of South Alabama, Mobile, AL, 36604, USA
| | - Alla V Klyuyeva
- Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Schools of Medicine and Dentistry, 720 20th Street South, Kaul 440B, Birmingham, AL, 35294, USA
| | - Kelli R Goggans
- Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Schools of Medicine and Dentistry, 720 20th Street South, Kaul 440B, Birmingham, AL, 35294, USA
| | - Natalia Y Kedishvili
- Department of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Schools of Medicine and Dentistry, 720 20th Street South, Kaul 440B, Birmingham, AL, 35294, USA
| | - E Alan Salter
- Department of Chemistry, University of South Alabama, 6040 USA South Drive, Mobile, AL, 36688, USA
| | - Andrzej Wierzbicki
- Department of Chemistry, University of South Alabama, 6040 USA South Drive, Mobile, AL, 36688, USA
| | - Marie E Migaud
- Mitchell Cancer Institute, University of South Alabama, Mobile, AL, 36604, USA
- Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL, 36604, USA
| | - Steven J Mullett
- Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA, 15261, USA
| | - Nathan A Yates
- Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA, 15261, USA
| | - Carlos J Camacho
- Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, 15261, USA
| | - Menico Rizzi
- Department of Pharmaceutical Sciences, University of Piemonte Orientale, Largo Donegani 2, 28100, Novara, Italy.
| | - Robert W Sobol
- Mitchell Cancer Institute, University of South Alabama, Mobile, AL, 36604, USA.
- Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL, 36604, USA.
| |
Collapse
|
7
|
Moretti A, Dato I, Gatto MC, Schiavoni M, Bernardo V, Kol A. 272 Combined rotational atherectomy and intravascular lithotripsy for heavy calcified coronary artery. Eur Heart J Suppl 2021. [DOI: 10.1093/eurheartj/suab134.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Aims
Percutaneous coronary intervention (PCI) of heavily calcified coronary lesions still represents a challenge for interventional cardiologists, with higher risk of immediate complications, late failure due to stent underexpansion or malapposition and consequent poor clinical outcome. Rotational atherectomy (RA) is a well-known calcium debulking modality. However, when coronary plaques present a significant amount of circumferential deep calcium, RA alone may not be able to achieve adequate lesion preparation. The combined use of intravascular lithotripsy (IVL) and RA, a technique called ‘Rotatripsy’, can be an effective approach in order to enable optimal stent implantation. We present a case of a calcific right coronary artery (RCA) PCI successfully treated by ‘Rotatripsy’ technique.
Methods and results
A 78-years-old man presented to our emergency department complaining of acute chest pain and dyspnoea. The electrocardiogram revealed ST-segment elevation in aVR and a diffuse ST-segment depression. Transthoracic echocardiography showed left ventricular anterior, septal, and apical walls akinesia. An urgent coronary angiography showed a critical distal left main (LM) stenosis involving the left anterior descending (LAD) artery ostium and a heavy calcified dominant RCA with two tandem sub-occlusive stenosis in the mid segment (Figure 1A). An immediate PCI with two drug eluting stents (DES) in the LM and LAD was performed. The patient was scheduled two days later for RCA PCI. RCA was engaged via left radial approach with a 6-Fr AL1 guiding catheter and the lesions were crossed with a Sion Blue wire. Using a Finecross MG microcatheter, an extra-support Rotawire was placed distally in the RCA. However, after multiple rotablation with 1.5 mm burr (Figure 1B), the mid segment lesion (Figure 1C) was still undilatable with a 3.5 mm non-compliant balloon (NCB) at 22 atm showing a partial dog bone effect (Figure 1D). We decided to attempt adjunctive IVL for calcium debulking. Using a Finecross MG and the trapping technique, a Gran Slam wire was placed distally; a 4.0 mm IVL balloon was delivered at the undilatable lesion and 80 pulses were applied (Figure 1E). Once the IVL treatment was completed (Figure 1F), a 4.0 mm NCB was inflated to 20 atm to further dilate the segment with an optimal expansion (Figure 1G). Finally, a DES Synergy 4.0 × 48 mm was implanted (Figure 1H) and it was post-dilated with a 4.5 mm NCB inflated to 22 atm (Figure 1I) with a perfect angiographic result (Figure 1J).
Conclusions
Coronary calcifications can lead to stent underexpansion, which is related to a higher rate of future complications, such as restenosis or thrombosis. If conventional lesion dilatations are not effective, alternative techniques should be considered (cutting balloon, scoring balloon, RA, orbital atherectomy, IVL). In case of circumferential deep calcium plaques, RA may not be able to achieve an adequate lesion preparation. RA allows the treatment of intimal calcium and permits to cross balloons or stents through severe lesions. However, when adequate expansion of the balloons is not achieved after RA, Shockwave IVL, that is not usually able to cross critical stenosis due to its bulky profile, represents an optimal complementary device, in order to fracture deep calcium and facilitate stent delivery and optimal expansion. In this case, we have successfully used the hybrid approach called ‘Rotatripsy’, which combines RA and IVL, in order to avoid more aggressive RA, which would have required the use of 7-Fr guiding catheter setting and may have increased the risk of complications.
Collapse
Affiliation(s)
- Andrea Moretti
- Department of Cardiology, San Camillo de Lellis Hospital, Rieti, Italy
| | - Ilaria Dato
- Department of Cardiology, San Camillo de Lellis Hospital, Rieti, Italy
| | | | - Marzia Schiavoni
- Department of Cardiology, San Camillo de Lellis Hospital, Rieti, Italy
| | - Vincenzo Bernardo
- Department of Cardiology, San Camillo de Lellis Hospital, Rieti, Italy
| | - Amir Kol
- Department of Cardiology, San Camillo de Lellis Hospital, Rieti, Italy
| |
Collapse
|
8
|
Gatto MC, De Sanctis V, Percoco F, Persi A, Dominici T, Moretti A, Evangelista F, Mantica M, Kol A. Combined therapy with subcutaneous implantable cardiac defibrillator and leadless pacemaker in a patient with persistent left superior vena cava and mega coronary sinus: A challenging case for the best treatment. J Arrhythm 2021; 37:1364-1367. [PMID: 34621440 PMCID: PMC8485798 DOI: 10.1002/joa3.12613] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 07/18/2021] [Accepted: 07/26/2021] [Indexed: 12/02/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | | | - Amir Kol
- Ospedale San Camillo De Lellis Rieti Italy
| |
Collapse
|
9
|
Moretti A. The im pact of climate change on mycotoxin and related fungi risks in Europe: current scenario and future perspectives. Toxicol Lett 2021. [DOI: 10.1016/s0378-4274(21)00321-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
10
|
Alexeev GD, Alexeev MG, Amoroso A, Andrieux V, Anosov V, Antoshkin A, Augsten K, Augustyniak W, Azevedo CDR, Badełek B, Balestra F, Ball M, Barth J, Beck R, Bedfer Y, Berenguer Antequera J, Bernhard J, Bodlak M, Bradamante F, Bressan A, Burtsev VE, Chang WC, Chatterjee C, Chiosso M, Chumakov AG, Chung SU, Cicuttin A, Correia PMM, Crespo ML, D'Ago D, Dalla Torre S, Dasgupta SS, Dasgupta S, Denisenko I, Denisov OY, Donskov SV, Doshita N, Dreisbach C, Dünnweber W, Dusaev RR, Efremov A, Eversheim PD, Faccioli P, Faessler M, Finger M, Finger M, Fischer H, Franco C, Friedrich JM, Frolov V, Gautheron F, Gavrichtchouk OP, Gerassimov S, Giarra J, Gnesi I, Gorzellik M, Grasso A, Gridin A, Grosse Perdekamp M, Grube B, Guskov A, von Harrach D, Heitz R, Herrmann F, Horikawa N, d'Hose N, Hsieh CY, Huber S, Ishimoto S, Ivanov A, Iwata T, Jandek M, Jary V, Joosten R, Jörg P, Kabuß E, Kaspar F, Kerbizi A, Ketzer B, Khaustov GV, Khokhlov YA, Kisselev Y, Klein F, Koivuniemi JH, Kolosov VN, Kondo Horikawa K, Konorov I, Konstantinov VF, Kotzinian AM, Kouznetsov OM, Koval A, Kral Z, Krinner F, Kulinich Y, Kunne F, Kurek K, Kurjata RP, Kveton A, Lavickova K, Levorato S, Lian YS, Lichtenstadt J, Lin PJ, Longo R, Lyubovitskij VE, Maggiora A, Magnon A, Makins N, Makke N, Mallot GK, Maltsev A, Mamon SA, Marianski B, Martin A, Marzec J, Matoušek J, Matsuda T, Mattson G, Meshcheryakov GV, Meyer M, Meyer W, Mikhailov YV, Mikhasenko M, Mitrofanov E, Mitrofanov N, Miyachi Y, Moretti A, Nagaytsev A, Naim C, Neyret D, Nový J, Nowak WD, Nukazuka G, Nunes AS, Olshevsky AG, Ostrick M, Panzieri D, Parsamyan B, Paul S, Pekeler H, Peng JC, Pešek M, Peshekhonov DV, Pešková M, Pierre N, Platchkov S, Pochodzalla J, Polyakov VA, Pretz J, Quaresma M, Quintans C, Reicherz G, Riedl C, Rudnicki T, Ryabchikov DI, Rybnikov A, Rychter A, Samoylenko VD, Sandacz A, Sarkar S, Savin IA, Sbrizzai G, Schmieden H, Selyunin A, Sinha L, Slunecka M, Smolik J, Srnka A, Steffen D, Stolarski M, Subrt O, Sulc M, Suzuki H, Sznajder P, Tessaro S, Tessarotto F, Thiel A, Tomsa J, Tosello F, Townsend A, Tskhay V, Uhl S, Vasilishin BI, Vauth A, Veit BM, Veloso J, Ventura B, Vidon A, Virius M, Wagner M, Wallner S, Zaremba K, Zavada P, Zavertyaev M, Zemko M, Zemlyanichkina E, Zhao Y, Ziembicki M. Triangle Singularity as the Origin of the a_{1}(1420). Phys Rev Lett 2021; 127:082501. [PMID: 34477443 DOI: 10.1103/physrevlett.127.082501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2020] [Revised: 05/04/2021] [Accepted: 05/26/2021] [Indexed: 06/13/2023]
Abstract
The COMPASS Collaboration experiment recently discovered a new isovector resonancelike signal with axial-vector quantum numbers, the a_{1}(1420), decaying to f_{0}(980)π. With a mass too close to and a width smaller than the axial-vector ground state a_{1}(1260), it was immediately interpreted as a new light exotic meson, similar to the X, Y, Z states in the hidden-charm sector. We show that a resonancelike signal fully matching the experimental data is produced by the decay of the a_{1}(1260) resonance into K^{*}(→Kπ)K[over ¯] and subsequent rescattering through a triangle singularity into the coupled f_{0}(980)π channel. The amplitude for this process is calculated using a new approach based on dispersion relations. The triangle-singularity model is fitted to the partial-wave data of the COMPASS experiment. Despite having fewer parameters, this fit shows a slightly better quality than the one using a resonance hypothesis and thus eliminates the need for an additional resonance in order to describe the data. We thereby demonstrate for the first time in the light-meson sector that a resonancelike structure in the experimental data can be described by rescattering through a triangle singularity, providing evidence for a genuine three-body effect.
Collapse
Affiliation(s)
- G D Alexeev
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M G Alexeev
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - A Amoroso
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - V Andrieux
- CERN, 1211 Geneva 23, Switzerland
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - V Anosov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - A Antoshkin
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - K Augsten
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
- Czech Technical University in Prague, 16636 Prague, Czech Republic
| | - W Augustyniak
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
| | - C D R Azevedo
- Department of Physics, University of Aveiro, I3N, 3810-193 Aveiro, Portugal
| | - B Badełek
- Faculty of Physics, University of Warsaw, 02-093 Warsaw, Poland
| | - F Balestra
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - M Ball
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - J Barth
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - R Beck
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - Y Bedfer
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - J Berenguer Antequera
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - J Bernhard
- CERN, 1211 Geneva 23, Switzerland
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - M Bodlak
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | | | - A Bressan
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | - V E Burtsev
- Tomsk Polytechnic University, 634050 Tomsk, Russia
| | - W-C Chang
- Academia Sinica, Institute of Physics, Taipei 11529, Taiwan
| | - C Chatterjee
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | - M Chiosso
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - A G Chumakov
- Tomsk Polytechnic University, 634050 Tomsk, Russia
| | - S-U Chung
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - A Cicuttin
- Trieste Section of INFN, 34127 Trieste, Italy
| | - P M M Correia
- Department of Physics, University of Aveiro, I3N, 3810-193 Aveiro, Portugal
| | - M L Crespo
- Trieste Section of INFN, 34127 Trieste, Italy
| | - D D'Ago
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | | | - S S Dasgupta
- Matrivani Institute of Experimental Research & Education, Calcutta-700 030, India
| | - S Dasgupta
- Trieste Section of INFN, 34127 Trieste, Italy
| | - I Denisenko
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | | | - S V Donskov
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | - N Doshita
- Yamagata University, Yamagata 992-8510, Japan
| | - Ch Dreisbach
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - W Dünnweber
- Department of Physics, University of Aveiro, I3N, 3810-193 Aveiro, Portugal
- Institut für Experimentalphysik, Universität Bochum, 44780 Bochum, Germany
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- Physikalisches Institut, Universität Bonn, 53115 Bonn, Germany
- Institute of Scientific Instruments of the CAS, 61264 Brno, Czech Republic
- Matrivani Institute of Experimental Research & Education, Calcutta-700 030, India
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
- CERN, 1211 Geneva 23, Switzerland
- Technical University in Liberec, 46117 Liberec, Czech Republic
- LIP, 1649-003 Lisbon, Portugal
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
- University of Miyazaki, Miyazaki 889-2192, Japan
- Lebedev Physical Institute, 119991 Moscow, Russia
- Physik Department, Technische Universität München, 85748 Garching, Germany
- Nagoya University, 464 Nagoya, Japan
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
- Czech Technical University in Prague, 16636 Prague, Czech Republic
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- Academia Sinica, Institute of Physics, Taipei 11529, Taiwan
- School of Physics and Astronomy, Tel Aviv University, 69978 Tel Aviv, Israel
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
- Tomsk Polytechnic University, 634050 Tomsk, Russia
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
- Faculty of Physics, University of Warsaw, 02-093 Warsaw, Poland
- Institute of Radioelectronics, Warsaw University of Technology, 00-665 Warsaw, Poland
- Yamagata University, Yamagata 992-8510, Japan
| | - R R Dusaev
- Tomsk Polytechnic University, 634050 Tomsk, Russia
| | - A Efremov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - P D Eversheim
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | | | - M Faessler
- Department of Physics, University of Aveiro, I3N, 3810-193 Aveiro, Portugal
- Institut für Experimentalphysik, Universität Bochum, 44780 Bochum, Germany
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- Physikalisches Institut, Universität Bonn, 53115 Bonn, Germany
- Institute of Scientific Instruments of the CAS, 61264 Brno, Czech Republic
- Matrivani Institute of Experimental Research & Education, Calcutta-700 030, India
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
- CERN, 1211 Geneva 23, Switzerland
- Technical University in Liberec, 46117 Liberec, Czech Republic
- LIP, 1649-003 Lisbon, Portugal
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
- University of Miyazaki, Miyazaki 889-2192, Japan
- Lebedev Physical Institute, 119991 Moscow, Russia
- Physik Department, Technische Universität München, 85748 Garching, Germany
- Nagoya University, 464 Nagoya, Japan
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
- Czech Technical University in Prague, 16636 Prague, Czech Republic
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- Academia Sinica, Institute of Physics, Taipei 11529, Taiwan
- School of Physics and Astronomy, Tel Aviv University, 69978 Tel Aviv, Israel
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
- Tomsk Polytechnic University, 634050 Tomsk, Russia
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
- Faculty of Physics, University of Warsaw, 02-093 Warsaw, Poland
- Institute of Radioelectronics, Warsaw University of Technology, 00-665 Warsaw, Poland
- Yamagata University, Yamagata 992-8510, Japan
| | - M Finger
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - M Finger
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - H Fischer
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | | | - J M Friedrich
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - V Frolov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
- CERN, 1211 Geneva 23, Switzerland
| | - F Gautheron
- Institut für Experimentalphysik, Universität Bochum, 44780 Bochum, Germany
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - O P Gavrichtchouk
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - S Gerassimov
- Lebedev Physical Institute, 119991 Moscow, Russia
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - J Giarra
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - I Gnesi
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - M Gorzellik
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - A Grasso
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - A Gridin
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M Grosse Perdekamp
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - B Grube
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - A Guskov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - D von Harrach
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - R Heitz
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - F Herrmann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | | | - N d'Hose
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - C-Y Hsieh
- Academia Sinica, Institute of Physics, Taipei 11529, Taiwan
| | - S Huber
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - S Ishimoto
- Yamagata University, Yamagata 992-8510, Japan
| | - A Ivanov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - T Iwata
- Yamagata University, Yamagata 992-8510, Japan
| | - M Jandek
- Czech Technical University in Prague, 16636 Prague, Czech Republic
| | - V Jary
- Czech Technical University in Prague, 16636 Prague, Czech Republic
| | - R Joosten
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - P Jörg
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - E Kabuß
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - F Kaspar
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - A Kerbizi
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | - B Ketzer
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - G V Khaustov
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | - Yu A Khokhlov
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | - Yu Kisselev
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - F Klein
- Physikalisches Institut, Universität Bonn, 53115 Bonn, Germany
| | - J H Koivuniemi
- Institut für Experimentalphysik, Universität Bochum, 44780 Bochum, Germany
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - V N Kolosov
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | | | - I Konorov
- Lebedev Physical Institute, 119991 Moscow, Russia
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - V F Konstantinov
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | | | - O M Kouznetsov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - A Koval
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
| | - Z Kral
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - F Krinner
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - Y Kulinich
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - F Kunne
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - K Kurek
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
| | - R P Kurjata
- Institute of Radioelectronics, Warsaw University of Technology, 00-665 Warsaw, Poland
| | - A Kveton
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - K Lavickova
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - S Levorato
- CERN, 1211 Geneva 23, Switzerland
- Trieste Section of INFN, 34127 Trieste, Italy
| | - Y-S Lian
- Academia Sinica, Institute of Physics, Taipei 11529, Taiwan
| | - J Lichtenstadt
- School of Physics and Astronomy, Tel Aviv University, 69978 Tel Aviv, Israel
| | - P-J Lin
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - R Longo
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | | | - A Maggiora
- Torino Section of INFN, 10125 Torino, Italy
| | - A Magnon
- Matrivani Institute of Experimental Research & Education, Calcutta-700 030, India
| | - N Makins
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - N Makke
- Trieste Section of INFN, 34127 Trieste, Italy
| | - G K Mallot
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
- CERN, 1211 Geneva 23, Switzerland
| | - A Maltsev
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - S A Mamon
- Tomsk Polytechnic University, 634050 Tomsk, Russia
| | - B Marianski
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
| | - A Martin
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | - J Marzec
- Institute of Radioelectronics, Warsaw University of Technology, 00-665 Warsaw, Poland
| | - J Matoušek
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | - T Matsuda
- University of Miyazaki, Miyazaki 889-2192, Japan
| | - G Mattson
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - G V Meshcheryakov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M Meyer
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - W Meyer
- Institut für Experimentalphysik, Universität Bochum, 44780 Bochum, Germany
| | - Yu V Mikhailov
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | - M Mikhasenko
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- CERN, 1211 Geneva 23, Switzerland
| | - E Mitrofanov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - N Mitrofanov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - Y Miyachi
- Yamagata University, Yamagata 992-8510, Japan
| | - A Moretti
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | - A Nagaytsev
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - C Naim
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - D Neyret
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - J Nový
- Czech Technical University in Prague, 16636 Prague, Czech Republic
| | - W-D Nowak
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - G Nukazuka
- Yamagata University, Yamagata 992-8510, Japan
| | | | - A G Olshevsky
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M Ostrick
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - D Panzieri
- Torino Section of INFN, 10125 Torino, Italy
| | - B Parsamyan
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - S Paul
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - H Pekeler
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - J-C Peng
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - M Pešek
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - D V Peshekhonov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M Pešková
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - N Pierre
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - S Platchkov
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - J Pochodzalla
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - V A Polyakov
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | - J Pretz
- Physikalisches Institut, Universität Bonn, 53115 Bonn, Germany
| | - M Quaresma
- LIP, 1649-003 Lisbon, Portugal
- Academia Sinica, Institute of Physics, Taipei 11529, Taiwan
| | | | - G Reicherz
- Institut für Experimentalphysik, Universität Bochum, 44780 Bochum, Germany
| | - C Riedl
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - T Rudnicki
- Faculty of Physics, University of Warsaw, 02-093 Warsaw, Poland
| | - D I Ryabchikov
- Physik Department, Technische Universität München, 85748 Garching, Germany
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | - A Rybnikov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - A Rychter
- Institute of Radioelectronics, Warsaw University of Technology, 00-665 Warsaw, Poland
| | - V D Samoylenko
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | - A Sandacz
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
| | - S Sarkar
- Matrivani Institute of Experimental Research & Education, Calcutta-700 030, India
| | - I A Savin
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - G Sbrizzai
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | - H Schmieden
- Physikalisches Institut, Universität Bonn, 53115 Bonn, Germany
| | - A Selyunin
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - L Sinha
- Matrivani Institute of Experimental Research & Education, Calcutta-700 030, India
| | - M Slunecka
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - J Smolik
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - A Srnka
- Institute of Scientific Instruments of the CAS, 61264 Brno, Czech Republic
| | - D Steffen
- CERN, 1211 Geneva 23, Switzerland
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | | | - O Subrt
- CERN, 1211 Geneva 23, Switzerland
- Czech Technical University in Prague, 16636 Prague, Czech Republic
| | - M Sulc
- Technical University in Liberec, 46117 Liberec, Czech Republic
| | - H Suzuki
- Yamagata University, Yamagata 992-8510, Japan
| | - P Sznajder
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
| | - S Tessaro
- Trieste Section of INFN, 34127 Trieste, Italy
| | - F Tessarotto
- CERN, 1211 Geneva 23, Switzerland
- Trieste Section of INFN, 34127 Trieste, Italy
| | - A Thiel
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - J Tomsa
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - F Tosello
- Torino Section of INFN, 10125 Torino, Italy
| | - A Townsend
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - V Tskhay
- Lebedev Physical Institute, 119991 Moscow, Russia
| | - S Uhl
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | | | - A Vauth
- Physikalisches Institut, Universität Bonn, 53115 Bonn, Germany
- CERN, 1211 Geneva 23, Switzerland
| | - B M Veit
- CERN, 1211 Geneva 23, Switzerland
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - J Veloso
- Department of Physics, University of Aveiro, I3N, 3810-193 Aveiro, Portugal
| | - B Ventura
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - A Vidon
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - M Virius
- Czech Technical University in Prague, 16636 Prague, Czech Republic
| | - M Wagner
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - S Wallner
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - K Zaremba
- Institute of Radioelectronics, Warsaw University of Technology, 00-665 Warsaw, Poland
| | - P Zavada
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M Zavertyaev
- Lebedev Physical Institute, 119991 Moscow, Russia
| | - M Zemko
- CERN, 1211 Geneva 23, Switzerland
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - E Zemlyanichkina
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - Y Zhao
- Trieste Section of INFN, 34127 Trieste, Italy
| | - M Ziembicki
- Institute of Radioelectronics, Warsaw University of Technology, 00-665 Warsaw, Poland
| |
Collapse
|
11
|
Cecoro G, Paoletta M, Annunziata M, Laino L, Nastri L, Gimigliano F, Liguori S, Toro G, Moretti A, Guida L, Iolascon G. The role of bone anabolic drugs in the management of periodontitis: a scoping review. Eur Cell Mater 2021; 41:316-331. [PMID: 33733451 DOI: 10.22203/ecm.v041a20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The aim of this scoping review was to summarise current knowledge about the effects of bone anabolic drugs on periodontitis, in order to identify new therapeutic strategies for preventing disease progression and reducing tooth loss. A technical expert panel (TEP) was established of 11 medical specialists, including periodontists and bone specialists that followed the PRISMA-ScR model to perform the scoping review and considered for eligibility both pre-clinical and clinical studies published in the English language up to September 2020. 716 items were initially found. After duplicate removal and screening of articles for eligibility criteria, 25 articles published between 2001 and 2019 were selected. Only studies concerning teriparatide, strontium ranelate, sclerostin antibodies and DKK1 antibodies met the eligibility criteria. In particular, only for teriparatide were there both clinical studies and experimental studies available, while for other bone anabolic drugs only animal studies were found. Available evidence about the use of bone anabolic drugs in periodontology demonstrates beneficial effects of these agents on biological pathways and histological parameters involved in periodontal tissue regeneration that suggest relevant clinical implications for the management of periodontitis.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - A Moretti
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", 80138 Naples,
| | | | | |
Collapse
|
12
|
Barbagallo F, Margani G, Marino EM, Moretti A, Tardo C. IMPACT OF RETROFIT OF RC FRAMES BY CLT PANELS AND FRICTION DAMPERS. Proceedings of the 8th International Conference on Computational Methods in Structural Dynamics and Earthquake Engineering (COMPDYN 2015) 2021. [DOI: 10.7712/120121.8636.18851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
|
13
|
Pelliccia F, Pasceri V, Moretti A, Tanzilli G, Speciale G, Gaudio C. Endothelial progenitor cells predict long-term outcome in patients with coronary artery disease: Ten-year follow-up of the PROCREATION extended study. Int J Cardiol 2020; 318:123-125. [DOI: 10.1016/j.ijcard.2020.06.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Revised: 05/13/2020] [Accepted: 06/01/2020] [Indexed: 01/26/2023]
|
14
|
Moretti A, Viceconte N, Pelliccia F, Tanzilli G. Partial Sub-Struts Stenting Technique for Emergency Treatment of Very Late LAD Stent Thrombosis: A Case Report. Cardiovascular Revascularization Medicine 2020; 21:83-85. [DOI: 10.1016/j.carrev.2020.05.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2020] [Revised: 05/24/2020] [Accepted: 05/26/2020] [Indexed: 10/24/2022]
|
15
|
Masiello M, Somma S, Haidukowski M, Logrieco AF, Moretti A. Genetic polymorphisms associated to SDHI fungicides resistance in selected Aspergillus flavus strains and relation with aflatoxin production. Int J Food Microbiol 2020; 334:108799. [PMID: 32799117 DOI: 10.1016/j.ijfoodmicro.2020.108799] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Revised: 07/17/2020] [Accepted: 07/24/2020] [Indexed: 12/18/2022]
Abstract
Aspergillus flavus is a common and ubiquitous fungal species able to colonize several agricultural commodities, in both pre- and post-harvest conditions. This species represents a very harmful plant pathogen for its ability to synthesize aflatoxin B1, responsible for human primary hepatocellular carcinoma and classified as a group I (human carcinogenic) by the International Agency for Research on Cancer. Several approaches have been proposed to control A. flavus development and related aflatoxin production in field and storage conditions. The Succinate Dehydrogenase Inhibitor (SDHI) fungicide boscalid has been shown to control A. flavus growth and aflatoxin contamination both in vitro and in field experiments. However, this compound is classified as medium-high risk fungicide for triggering fungal resistance and, indeed, resistant strains can occur on crops treated with boscalid. In this paper, we selected laboratory A. flavus strains resistant to boscalid grown on agar medium containing 50 mg/L of boscalid. In order to investigate the molecular mechanism responsible for the resistant phenotype, specific primer pairs were designed to amplify the whole SdhB, SdhC and SdhD genes. By amino acid sequence analysis, two point mutations, Tyrosine replacing Histidine at codon 249 of SdhB (H249Y) and Arginine replacing Glycine at codon 91 of SdhC (G91R), were identified. The effect of SDHI boscalid and isopyrazam on mycelial growth and conidial germination was evaluated. Both resistant genotypes showed high resistance (MIC and EC50 > 1000 mg/L) to boscalid. A positive cross-resistance was found between boscalid and isopyrazam. Specific sub-lethal doses of both fungicides (0.5 mg/L of boscalid and 0.01 mg/L of isopyrazam) interfered with the mechanisms associated to pigmentation of colonies. In particular, fungal colonies appeared depigmented lacking the typical A. flavus green colour shown on un-amended fungicide medium. A strict correlation between lack of pigmentation and increasing aflatoxin production was also observed.
Collapse
Affiliation(s)
- M Masiello
- Institute of Sciences of Food Production, Research National Council (ISPA-CNR), Via Amendola 122/O, 70126 Bari, Italy.
| | - S Somma
- Institute of Sciences of Food Production, Research National Council (ISPA-CNR), Via Amendola 122/O, 70126 Bari, Italy.
| | - M Haidukowski
- Institute of Sciences of Food Production, Research National Council (ISPA-CNR), Via Amendola 122/O, 70126 Bari, Italy.
| | - A F Logrieco
- Institute of Sciences of Food Production, Research National Council (ISPA-CNR), Via Amendola 122/O, 70126 Bari, Italy.
| | - A Moretti
- Institute of Sciences of Food Production, Research National Council (ISPA-CNR), Via Amendola 122/O, 70126 Bari, Italy.
| |
Collapse
|
16
|
Cagini C, Mariniello M, Messina M, Muzi A, Balducci C, Moretti A, Levorato L, Mencacci A. The role of ozonized oil and a combination of tobramycin/dexamethasone eye drops in the treatment of viral conjunctivitis: a randomized clinical trial. Int Ophthalmol 2020; 40:3209-3215. [PMID: 32696102 PMCID: PMC7669761 DOI: 10.1007/s10792-020-01503-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Accepted: 06/30/2020] [Indexed: 02/07/2023]
Abstract
Purpose To determine whether topical tobramycin 0.3%/dexamethasone 0.1% plus ozonized oil eye drops reduces clinical signs and infectious viral titers of presumed viral conjunctivitis more than tobramycin/dexamethasone eye drops alone. Methods Prospective, single-blind, randomized, parallel-groups trial. Eighty patients with a clinical diagnosis of presumed viral conjunctivitis were randomizedly divided into two treatment groups: a study group and a control group, 40 for each group. Patients in the study group received topical tobramycin 0.3%/dexamethasone 0.1% eye drops, plus ozonized oil eye drops, both four times daily; patients in the control group received only topical tobramycin 0.3%/dexamethasone eye drops four times daily. The treatment was for seven days in both groups. Swabs were taken from the conjunctival fornix for adenovirus PCR analysis on the day of recruitment and at seven days follow-up. Clinical signs were also recorded on the day of recruitment and at follow-up examination: the main outcomes were conjunctival injection and conjunctival chemosis, graded on a 4-point clinical scale, presence or absence of superficial punctate keratitis and subepithelial corneal infiltrates. Results No statistically significant difference was reached in adenoviral infection negativization between the two groups, although the study group showed a higher number of PCR negative results at seven days follow-up. PCR real time detected adenoviral infection in 17 of 24 patients on the day of recruitment and it was positive in 4 patients on the seventh day (viral positivity reduction of 76%). In the control group PCR was positive for adenovirus in 18 of 24 patients on the day of recruitment and in 7 patients at seven days follow-up (reduction of 61%). There was statistically significant difference on conjunctival clinical signs between the study and control groups. Significant difference was also found on superficial punctate keratitis resolution between the study and the control group. In the former superficial punctate keratitis was detected in 14 eyes on the first day and in 5 eyes after seven days while in the latter superficial punctate keratitis was found in 124 eyes on the first day and in 6 eyes on the seventh day. No difference was found in subepithelial corneal infiltrates appearance between the two groups. Conclusions The use of ozonized-oil containing eye drops in combination with topical tobramycin 0.3%/dexamethasone 0.1% eye drops four times daily seems to reduce the signs of conjunctivitis, and the duration of viral infection, although it does not affect the subepithelial corneal infiltrates appearance.
Collapse
Affiliation(s)
- C Cagini
- Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy.
| | - M Mariniello
- Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy
| | - M Messina
- Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy
| | - A Muzi
- Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy
| | - C Balducci
- Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy
| | - A Moretti
- Microbiology Unit, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy
| | - L Levorato
- Microbiology Unit, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy
| | - A Mencacci
- Microbiology Unit, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy
| |
Collapse
|
17
|
Sanz Sánchez J, Chiarito M, Cortese B, Moretti A, Pagnotta P, Reimers B, Stefanini GG, Ferrante G. Drug-Coated balloons vs drug-eluting stents for the treatment of small coronary artery disease: A meta-analysis of randomized trials. Catheter Cardiovasc Interv 2020; 98:66-75. [PMID: 32592437 DOI: 10.1002/ccd.29111] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Revised: 05/11/2020] [Accepted: 05/31/2020] [Indexed: 01/08/2023]
Abstract
OBJECTIVES AND BACKGROUND There is conflicting evidence about the effects of drug-coated balloons (DCB) compared with drug-eluting stents (DES) in patients with native small vessel coronary artery disease (CAD). METHODS The PubMed, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov databases and main international conference proceedings were searched for randomized controlled trials (RCT) comparing DCB versus DES in patients with native small vessel CAD. Data were pooled by meta-analysis using a random-effects model. The primary endpoint was target vessel revascularization (TVR). Secondary clinical endpoints were: myocardial infarction (MI), target lesion revascularization (TLR), all-cause death, cardiac death, and stent thrombosis or target vessel thrombosis. Secondary angiographic outcomes were: in-segment restenosis, in-segment percentage-diameter stenosis, in-segment late lumen loss, in-segment net luminal gain, and in-segment minimal lumen diameter. RESULTS Five trials enrolling 1,459 patients were included. Mean clinical follow-up was 10.2 months. The use of DCB, compared with DES, was associated with similar risk of TVR (odds ratio [OR]: 0.97; 95% confidence interval [CI] 0.56 to 1.68; p = .92), TLR (OR: 1.74; 95% CI: 0.57 to 5.28; p = .33), all-cause death (OR: 1.03; 95% CI: 0.14 to 7.48; p = .98), with a trend toward a lower risk of MI (OR: 0.49; 95% CI: 0.23 to 1.03; p = .06), and with significant lower risk of vessel thrombosis (OR: 0.12; 95% CI: 0.01 to 0.94; p = .04). DCB use was associated with similar risk of angiographic restenosis (OR: 1.12; 95% CI 0.69 to 1.84; p = .64), comparable late luminal loss (standardized mean difference (SMD): -0.18; 95% CI: -0.39 to 0.03; p = .09), while leading to significant higher percentage diameter stenosis (SMD: 0.27; 95% CI 0.12 to 0.41; p < .01) and smaller minimal luminal diameter (SMD: -0.52; 95% CI: -0.86 to -0.18; p = .003). CONCLUSION Compared with DES, the use of DCB for the treatment of native small vessel CAD is associated with similar TVR and restenosis and reduces the risk of vessel thrombosis, although DES implantation yields slightly better angiographic surrogate endpoints.
Collapse
Affiliation(s)
- Jorge Sanz Sánchez
- Department of Biomedical Sciences, Humanitas University, Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, IRCCS, Via Alessandro Manzoni, 56, Rozzano (Milan), 20089, Italy
| | - Mauro Chiarito
- Department of Biomedical Sciences, Humanitas University, Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, IRCCS, Via Alessandro Manzoni, 56, Rozzano (Milan), 20089, Italy
| | | | - Andrea Moretti
- Department of Heart and Great Vessels, Sapienza University of Rome, Rome, Italy
| | - Paolo Pagnotta
- Department of Biomedical Sciences, Humanitas University, Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, IRCCS, Via Alessandro Manzoni, 56, Rozzano (Milan), 20089, Italy
| | - Bernhard Reimers
- Department of Biomedical Sciences, Humanitas University, Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, IRCCS, Via Alessandro Manzoni, 56, Rozzano (Milan), 20089, Italy
| | - Giulio G Stefanini
- Department of Biomedical Sciences, Humanitas University, Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, IRCCS, Via Alessandro Manzoni, 56, Rozzano (Milan), 20089, Italy
| | - Giuseppe Ferrante
- Department of Biomedical Sciences, Humanitas University, Department of Cardiovascular Medicine, Humanitas Clinical and Research Center, IRCCS, Via Alessandro Manzoni, 56, Rozzano (Milan), 20089, Italy
| |
Collapse
|
18
|
Cipolletta E, DI Matteo A, Brunori G, Moretti A, Grassi W, Filippucci E. THU0407 THE VALUE OF SONOGRAPHY IN THE INTERCRITICAL PHASE OF GOUT. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Disease remission is the goal of therapy for many chronic rheumatic diseases. In 2016, provisional gout remission criteria were proposed (1). To the best of our knowledge, no studies have compared ultrasound (US) findings in gouty patients with and without remission.Objectives:To determine the prevalence of US pathologic findings in patients with gout fulfilling and not fulfilling the provisional remission criteria and to investigate the value of the US findings as predictors of a gouty flare within 6 months.Methods:Patients with a diagnosis of gout according to the 2015 classification criteria (2) were recruited in this prospective, monocentric study. The following clinical information was recorded at baseline and after 6 months: number of gouty flares in the preceding 6 months, number of subcutaneous tophi, current serum urate level, and patient reported outcomes (pain visual analogue scale and patient global assessment visual analogue scale). Bilateral US assessment of the following anatomical areas was performed (3): elbow, wrist, II metacarpophalangeal joint, knee, ankle and I metatarsophalangeal joint. US evidence of tophi, aggregates, double contour sign and synovitis were recorded according to the correspondent OMERACT definitions.Results:Forty-nine patients with gout were consecutively enrolled. The remission criteria were satisfied in 9 (18.4%) patients. Monosodium urate (MSU) deposits and findings of synovitis were observed by US less frequently in patients in remission (55.6% and 22.2%), compared with those not fulfilling the criteria (100.0% and 72.5%) (p values<0.01). The US MSU total score was 1.0; 0.0–2.0 (median and inter-quartile range) for patients in remission, compared with 6.0; 5.0–7.0 for those not fulfilling the criteria (p<0.01). US synovitis total score was significantly correlated with patient global assessment (R=0.55, p<0.01), patient pain (R=0.51, p<0.01) and number of gouty attacks in the previous 6 months (R=0.36, p=0.03), whereas MSU total score was associated with the number of gouty attacks in the previous 6 months (R=0.49, p<0.01), the number of subcutaneous tophi (R=0.45, p<0.01), patient pain (R=0.41, p=0.01), patient global assessment (R=0.41, p<0.01). At logistic regression analysis, the presence of subcutaneous tophi (OR=2.8, p=0.02), CRP level (OR=6.5, p=0.04) and US synovitis score (OR=2.0, p=0.04) and were predictors of subsequent development of gouty flare within 6 months.Conclusion:This study provides new insights into the inter-critical phase of gout, highlighting the clinical relevance of US synovitis as a predictor of subsequent development of gouty flare and joint pain. Despite MSU deposits are still detectable in patients satisfying the 2016 provisional remission criteria for gout, the remission is associated with less US detected MSU deposits.References:[1]de Lautour H, et al. Development of preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care Res 2016[2]Neogi T, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2015[3]Naredo E, et al. Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis 2014Disclosure of Interests: :Edoardo Cipolletta: None declared, Andrea Di Matteo Grant/research support from: the publication was conducted while Dr. Di Matteo was an ARTICULUM fellow, Giada Brunori: None declared, Antonella Moretti: None declared, Walter Grassi Speakers bureau: Prof. Grassi reports personal fees from AbbVie, personal fees from Celgene, personal fees from Grünenthal, personal fees from Pfizer, personal fees from Union Chimique Belge Pharma, outside the submitted work., Emilio Filippucci Speakers bureau: Dr. Filippucci reports personal fees from AbbVie, personal fees from Bristol-Myers Squibb, personal fees from Celgene, personal fees from Roche, personal fees from Union Chimique Belge Pharma, personal fees from Pfizer, outside the submitted work.
Collapse
|
19
|
Moretti A, Chiarito M, Sanz-Sánchez J, Petriello G, Stefanini G. [Acute coronary syndrome in a patient with a residual aortic dissection flap after supracoronary aortic replacement: the role of intravascular ultrasound]. G Ital Cardiol (Rome) 2020; 21:46S-49S. [PMID: 32250370 DOI: 10.1714/3336.33074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Acute chest pain caused by aortic dissection (AD) or acute myocardial infarction (AMI) is one of the most serious medical emergencies and requires a very quick differential diagnosis to choose the best timing for treatment. AD and AMI are often manifested with similar symptoms, making it difficult to differentially diagnose these two conditions. After supracoronary aortic repair for type A AD, small intimal flap could remain in the anastomosis area. Aortic intramural hematoma could extend to the coronary ostia causing an extrinsic compression. Intravascular ultrasound is a safe and effective methodology to distinguish an atherosclerotic plaque from an extrinsic compression. We present the case of a 68-year-old man, with a recent surgical correction of a type A AD, referred to our emergency department for an acute coronary syndrome.
Collapse
Affiliation(s)
- Andrea Moretti
- Dipartimento Cardiovascolare, IRCCS Istituto Clinico Humanitas, Rozzano (MI) - Dipartimento di Scienze Cardiovascolari, Sapienza Università di Roma, Roma
| | - Mauro Chiarito
- Dipartimento Cardiovascolare, IRCCS Istituto Clinico Humanitas, Rozzano (MI)
| | - Jorge Sanz-Sánchez
- Dipartimento Cardiovascolare, IRCCS Istituto Clinico Humanitas, Rozzano (MI)
| | - Gennaro Petriello
- Dipartimento Cardiovascolare, IRCCS Istituto Clinico Humanitas, Rozzano (MI)
| | - Giulio Stefanini
- Dipartimento Cardiovascolare, IRCCS Istituto Clinico Humanitas, Rozzano (MI)
| |
Collapse
|
20
|
Pirovano V, Brambilla E, Moretti A, Rizzato S, Abbiati G, Nava D, Rossi E. Synthesis of Cyclohepta[ b]indoles by (4 + 3) Cycloaddition of 2-Vinylindoles or 4 H-Furo[3,2- b]indoles with Oxyallyl Cations. J Org Chem 2020; 85:3265-3276. [PMID: 31975604 PMCID: PMC7997566 DOI: 10.1021/acs.joc.9b03117] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
![]()
The synthesis of cyclohepta[b]indole derivatives
through the dearomative (4 + 3) cycloaddition reaction of 2-vinylindoles
or 4H-furo[3,2-b]indoles with in
situ generated oxyallyl cations is reported. Oxyallyl cations are
generated from α-bromoketones in the presence of a base and
a perfluorinated solvent. Cyclohepta[b]indole scaffolds
are obtained under mild reaction conditions, in the absence of expensive
catalysts, starting from simple reagents, in good to excellent yields
and with complete diasteroselectivity. Preliminary expansion of the
scope to 3-vinylindoles and to aza-oxyallyl cations is reported.
Collapse
Affiliation(s)
- Valentina Pirovano
- Dipartimento di Scienze Farmaceutiche-Sezione di Chimica Generale e Organica "A. Marchesini", Università degli Studi di Milano, Via Venezian 21, 20133 Milano, Italy
| | - Elisa Brambilla
- Dipartimento di Scienze Farmaceutiche-Sezione di Chimica Generale e Organica "A. Marchesini", Università degli Studi di Milano, Via Venezian 21, 20133 Milano, Italy
| | - Andrea Moretti
- Dipartimento di Scienze Farmaceutiche-Sezione di Chimica Generale e Organica "A. Marchesini", Università degli Studi di Milano, Via Venezian 21, 20133 Milano, Italy
| | - Silvia Rizzato
- Dipartimento di Chimica, Università degli Studi di Milano, Via Golgi 19, 20133 Milano, Italy
| | - Giorgio Abbiati
- Dipartimento di Scienze Farmaceutiche-Sezione di Chimica Generale e Organica "A. Marchesini", Università degli Studi di Milano, Via Venezian 21, 20133 Milano, Italy
| | - Donatella Nava
- Dipartimento di Scienze Farmaceutiche-Sezione di Chimica Generale e Organica "A. Marchesini", Università degli Studi di Milano, Via Venezian 21, 20133 Milano, Italy
| | - Elisabetta Rossi
- Dipartimento di Scienze Farmaceutiche-Sezione di Chimica Generale e Organica "A. Marchesini", Università degli Studi di Milano, Via Venezian 21, 20133 Milano, Italy
| |
Collapse
|
21
|
Moretti A, Fonteyne L, Giesert F, Hoppmann P, Meier AB, Bozoglu T, Baehr A, Schneider CM, Sinnecker D, Klett K, Fröhlich T, Rahman FA, Haufe T, Sun S, Jurisch V, Kessler B, Hinkel R, Dirschinger R, Martens E, Jilek C, Graf A, Krebs S, Santamaria G, Kurome M, Zakhartchenko V, Campbell B, Voelse K, Wolf A, Ziegler T, Reichert S, Lee S, Flenkenthaler F, Dorn T, Jeremias I, Blum H, Dendorfer A, Schnieke A, Krause S, Walter MC, Klymiuk N, Laugwitz KL, Wolf E, Wurst W, Kupatt C. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nat Med 2020; 26:207-214. [PMID: 31988462 PMCID: PMC7212064 DOI: 10.1038/s41591-019-0738-2] [Citation(s) in RCA: 140] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2019] [Accepted: 12/11/2019] [Indexed: 11/09/2022]
Abstract
Frameshift mutations in the DMD gene, encoding dystrophin, cause Duchenne muscular dystrophy (DMD), leading to terminal muscle and heart failure in patients. Somatic gene editing by sequence-specific nucleases offers new options for restoring the DMD reading frame, resulting in expression of a shortened but largely functional dystrophin protein. Here, we validated this approach in a pig model of DMD lacking exon 52 of DMD (DMDΔ52), as well as in a corresponding patient-derived induced pluripotent stem cell model. In DMDΔ52 pigs1, intramuscular injection of adeno-associated viral vectors of serotype 9 carrying an intein-split Cas9 (ref. 2) and a pair of guide RNAs targeting sequences flanking exon 51 (AAV9-Cas9-gE51) induced expression of a shortened dystrophin (DMDΔ51-52) and improved skeletal muscle function. Moreover, systemic application of AAV9-Cas9-gE51 led to widespread dystrophin expression in muscle, including diaphragm and heart, prolonging survival and reducing arrhythmogenic vulnerability. Similarly, in induced pluripotent stem cell-derived myoblasts and cardiomyocytes of a patient lacking DMDΔ52, AAV6-Cas9-g51-mediated excision of exon 51 restored dystrophin expression and amelioreate skeletal myotube formation as well as abnormal cardiomyocyte Ca2+ handling and arrhythmogenic susceptibility. The ability of Cas9-mediated exon excision to improve DMD pathology in these translational models paves the way for new treatment approaches in patients with this devastating disease.
Collapse
Affiliation(s)
- A Moretti
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany.
| | - L Fonteyne
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
| | - F Giesert
- Institute of Developmental Genetics, Helmholtz Centre and Munich School of Life Sciences Weihenstephan, Technical University of Munich, Munich, Germany
| | - P Hoppmann
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - A B Meier
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - T Bozoglu
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - A Baehr
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - C M Schneider
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - D Sinnecker
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - K Klett
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - T Fröhlich
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - F Abdel Rahman
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - T Haufe
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - S Sun
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - V Jurisch
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - B Kessler
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - R Hinkel
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - R Dirschinger
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - E Martens
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - C Jilek
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - A Graf
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - S Krebs
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - G Santamaria
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - M Kurome
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - V Zakhartchenko
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - B Campbell
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - K Voelse
- Reseach Unit Apoptosis in Hemopoietic Stem Cells, Helmholtz Zentrum München, German Center for Environmental Health (HMGU), Munich, Germany
| | - A Wolf
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - T Ziegler
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - S Reichert
- Department of Neurology, Friedrich Baur Institute, LMU Munich, Munich, Germany
| | - S Lee
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - F Flenkenthaler
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - T Dorn
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - I Jeremias
- Reseach Unit Apoptosis in Hemopoietic Stem Cells, Helmholtz Zentrum München, German Center for Environmental Health (HMGU), Munich, Germany
| | - H Blum
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - A Dendorfer
- Walter Brendel Centre of Experimental Medicine, University Hospital, LMU Munich, Munich, Germany
| | - A Schnieke
- Chair of Livestock Biotechnology, School of Life Sciences Weihenstephan, Technical University of Munich, Munich, Germany
| | - S Krause
- Department of Neurology, Friedrich Baur Institute, LMU Munich, Munich, Germany
| | - M C Walter
- Department of Neurology, Friedrich Baur Institute, LMU Munich, Munich, Germany
| | - N Klymiuk
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - K L Laugwitz
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - E Wolf
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - W Wurst
- Institute of Developmental Genetics, Helmholtz Centre and Munich School of Life Sciences Weihenstephan, Technical University of Munich, Munich, Germany
- German Center for Neurodegenerative Diseases, Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - C Kupatt
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany.
| |
Collapse
|
22
|
Moretti A, Sanz Sanchez J, Petriello G, Gasparini GL. Ultra-Deep Guide Catheter Intubation for Direct Thromboaspiration in Acute Myocardial Infarction. Cardiovasc Revasc Med 2019; 20:49-50. [PMID: 31471271 DOI: 10.1016/j.carrev.2019.08.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2019] [Revised: 06/21/2019] [Accepted: 08/13/2019] [Indexed: 01/05/2023]
Abstract
Thrombus burden remains an important mortality risk factor during primary percutaneous coronary interventions (PCI), especially when associated with distal embolization of atheromatous debris (Sharma et al., 2016; Ibanez et al., 2018 [1,2]). Although routine thrombus aspiration during primary PCI in acute coronary syndrome (ACS) is not recommended (Sharma et al., 2016 [1]), some procedures become very challenging when thrombus removal and vessel reperfusion is not achieved with conventional dedicated devices. We describe a case of a 60-year old man with a late-comer infero-lateral ST-segment elevation myocardial infarction (STEMI) undergoing right coronary artery primary PCI. A high thrombotic burden was shown requiring an ultra-deep guide catheter intubation to perform a successful thromboaspiration and stenting.
Collapse
Affiliation(s)
- Andrea Moretti
- Department of Invasive Cardiology, Humanitas Research Hospital, Rozzano, Milan, Italy
| | - Jorge Sanz Sanchez
- Department of Invasive Cardiology, Humanitas Research Hospital, Rozzano, Milan, Italy
| | - Gennaro Petriello
- Department of Invasive Cardiology, Humanitas Research Hospital, Rozzano, Milan, Italy
| | - Gabriele L Gasparini
- Department of Invasive Cardiology, Humanitas Research Hospital, Rozzano, Milan, Italy.
| |
Collapse
|
23
|
Matteucci F, Solinas L, Turri V, Donati C, D'errico V, Moretti A, Bianchini D, Paganelli G, Gallegati D, Altini M. IntegoTM infusion system: cost effectiveness analysis focusing on dosimetry, sterility and management. Q J Nucl Med Mol Imaging 2019; 63:183-190. [PMID: 27387379 DOI: 10.23736/s1824-4785.16.02866-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
BACKGROUND Healthcare providers across Europe are facing an ever-growing demand in clinical PET referrals. Currently, it is estimated that the administration of the PET tracer accounts for approximately 40% of the unitary PET procedure reimbursement (uPETr). Although the cost of PET/CT is highly dependent on the radiopharmaceutical cost itself, little is known about the economic impact of the utilized administration method and the repercussions on staff radiation exposure. Our objective was to evaluate the cost-effectiveness of automatic injection/fractionation system Intego™ (Bayer HealthCare, MEDRAD Europe, Netherlands) for istaff radiation exposure reduction and to validate its use with 18F-choline (FCH). METHODS In order to validate Intego™ use with FCH we analyzed sterility, radioactivity fractionation accuracy and radiation protection for staff. We analyzed Intego™ impact on examination costs and its impact on organization efficiency. A cost-effectiveness analysis (CEA) was estimated as the incremental cost to reduce staff radiationexposure. RESULTS According to our data, Intego™ ensures both sterility and accuracy of FCH doses' activity, reducing, at the same time, the exposure to radiation either whole body and at the extremities (94% and 75% respectively for the technicians and complete reduction for physicians). Intego™'s variable unit costs are higher than the SA (respectively 1.8% and 0.4% of PET reimbursement), while staff costs are significantly higher with SA (respectively 0.27% and 1.57% of unitary PET reimbursement [uPETr]). In our simulation, based on a 2,450 PET yearly output, the differential costs were slightly higher by using Intego™™ (+ 14%). The incremental cost-effectiveness ratio (ICER) was equal to 1.1, i.e. the healthcare provider pays an additional cost of 0.38% of uPETr to obtain a significant reduction of staff radiation exposure (-4.5 µS). CONCLUSIONS Intego™, for its favorable results in terms of cost effectiveness, could be a useful tool in a nuclear medicine department, limiting the staff radiation exposure.
Collapse
Affiliation(s)
- Federica Matteucci
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy -
| | - Laura Solinas
- Planning and Control Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - Valentina Turri
- Health Care Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - Caterina Donati
- Pharmacy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - Vincenzo D'errico
- Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - Andrea Moretti
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - David Bianchini
- Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - Giovanni Paganelli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - Davide Gallegati
- Planning and Control Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| | - Mattia Altini
- Health Care Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Forlì-Cesena, Italy
| |
Collapse
|
24
|
Hohmann U, Nicolet J, Moretti A, Hothorn LA, Hothorn M. Publisher Correction: The SERK3 elongated allele defines a role for BIR ectodomains in brassinosteroid signalling. Nat Plants 2018; 4:732. [PMID: 30108298 DOI: 10.1038/s41477-018-0244-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
In the version of this Letter originally published, there were errors in the x axis labels of Figs 1, 2 and 4: in Fig. 1b, the label Col-0 should not have been included on the axis; in Fig. 2b BIR should have read BIR2, and DN221 should have read D122N; in Fig. 4f, pSEK3 should have read pSERK3. These figures have now been amended in all versions of the Letter.
Collapse
Affiliation(s)
- Ulrich Hohmann
- Structural Plant Biology Laboratory, Department of Botany and Plant Biology, University of Geneva, Geneva, Switzerland
| | - Joël Nicolet
- Structural Plant Biology Laboratory, Department of Botany and Plant Biology, University of Geneva, Geneva, Switzerland
| | - Andrea Moretti
- Structural Plant Biology Laboratory, Department of Botany and Plant Biology, University of Geneva, Geneva, Switzerland
| | - Ludwig A Hothorn
- Institute of Biostatistics, Leibniz University, Hannover, Germany
| | - Michael Hothorn
- Structural Plant Biology Laboratory, Department of Botany and Plant Biology, University of Geneva, Geneva, Switzerland.
| |
Collapse
|
25
|
My I, Laue S, Dressen M, Schmidt F, Brade T, Dorn T, Goedel A, Lahm H, Lickert H, Krane M, Moretti A, Laugwitz KL. P1848Primary cilium-autophagy-cell cycle axis defects impair cardiac progenitor specification in hypoplastic left heart syndrome. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- I My
- Hospital Rechts der Isar, Molecular Cardiology, first department of medicine, TU, Munich, Germany
| | - S Laue
- Hospital Rechts der Isar, Molecular Cardiology, first department of medicine, TU, Munich, Germany
| | - M Dressen
- Deutsches Herzzentrum Technische Universitat, Department of cardiovascular surgery, division of experimental surgery, Munich, Germany
| | - F Schmidt
- Helmholtz Center Munich - German Research Center for Environment and Health, Institute of diabetes and regeneration research, Munich, Germany
| | - T Brade
- Hospital Rechts der Isar, Molecular Cardiology, first department of medicine, TU, Munich, Germany
| | - T Dorn
- Hospital Rechts der Isar, Molecular Cardiology, first department of medicine, TU, Munich, Germany
| | - A Goedel
- Hospital Rechts der Isar, Molecular Cardiology, first department of medicine, TU, Munich, Germany
| | - H Lahm
- Deutsches Herzzentrum Technische Universitat, Department of cardiovascular surgery, division of experimental surgery, Munich, Germany
| | - H Lickert
- Helmholtz Center Munich - German Research Center for Environment and Health, Institute of diabetes and regeneration research, Munich, Germany
| | - M Krane
- Deutsches Herzzentrum Technische Universitat, Department of cardiovascular surgery, division of experimental surgery, Munich, Germany
| | - A Moretti
- Hospital Rechts der Isar, Molecular Cardiology, first department of medicine, TU, Munich, Germany
| | - K.-L Laugwitz
- Hospital Rechts der Isar, Molecular Cardiology, first department of medicine, TU, Munich, Germany
| |
Collapse
|
26
|
Hohmann U, Nicolet J, Moretti A, Hothorn LA, Hothorn M. The SERK3 elongated allele defines a role for BIR ectodomains in brassinosteroid signalling. Nat Plants 2018; 4:345-351. [PMID: 29735985 DOI: 10.1038/s41477-018-0150-9] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/10/2018] [Accepted: 04/09/2018] [Indexed: 05/27/2023]
Abstract
The leucine-rich repeat receptor kinase (LRR-RK) BRASSINOSTEROID INSENSITIVE 1 (BRI1) requires a shape-complementary SOMATIC EMBRYOGENESIS RECEPTOR KINASE (SERK) co-receptor for brassinosteroid sensing and receptor activation1. Interface mutations that weaken the interaction between receptor and co-receptor in vitro reduce brassinosteroid signalling responses2. The SERK3 elongated (elg) allele3-5 maps to the complex interface and shows enhanced brassinosteroid signalling, but surprisingly no tighter binding to the BRI1 ectodomain in vitro. Here, we report that rather than promoting the interaction with BRI1, the elg mutation disrupts the ability of the co-receptor to interact with the ectodomains of BRI1-ASSOCIATED-KINASE1 INTERACTING KINASE (BIR) receptor pseudokinases, negative regulators of LRR-RK signalling6. A conserved lateral surface patch in BIR LRR domains is required for targeting SERK co-receptors and the elg allele maps to the core of the complex interface in a 1.25 Å BIR3-SERK1 structure. Collectively, our structural, quantitative biochemical and genetic analyses suggest that brassinosteroid signalling complex formation is negatively regulated by BIR receptor ectodomains.
Collapse
Affiliation(s)
- Ulrich Hohmann
- Structural Plant Biology Laboratory, Department of Botany and Plant Biology, University of Geneva, Geneva, Switzerland
| | - Joël Nicolet
- Structural Plant Biology Laboratory, Department of Botany and Plant Biology, University of Geneva, Geneva, Switzerland
| | - Andrea Moretti
- Structural Plant Biology Laboratory, Department of Botany and Plant Biology, University of Geneva, Geneva, Switzerland
| | - Ludwig A Hothorn
- Institute of Biostatistics, Leibniz University, Hannover, Germany
| | - Michael Hothorn
- Structural Plant Biology Laboratory, Department of Botany and Plant Biology, University of Geneva, Geneva, Switzerland.
| |
Collapse
|
27
|
Moretti A, Bianchi F, Abbate IV, Gherardi G, Bonavita M, Passoni E, Nazzaro G, Bramati A, Dazzani MC, Piva S, Paternò E, Frungillo N, Farina G, La Verde N. Localized morphea after breast implant for breast cancer: A case report. Tumori 2018; 104:NP25-NP28. [PMID: 29714655 DOI: 10.1177/0300891618763209] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE Early breast cancer follow-up guidelines for patients who underwent surgery suggest a regular and accurate clinical examination of the breast area, for an early identification of cutaneous or subcutaneous breast cancer relapse. Nonetheless, breast skin lesions arising in patients treated with mastectomy for breast cancer can be caused by several diseases. A series of diagnostic hypotheses should be considered, not only focusing on cutaneous metastasis, but also on dermatologic and systemic diseases. CASE REPORT In February 2015, a 37-year-old patient underwent a right subcutaneous mastectomy for stage IIA breast cancer. Five months after beginning adjuvant chemotherapy, she noted hyperpigmentation and thickening of the skin on the right breast. Differential diagnosis included local relapse, skin infection, lymphoma, or primary cutaneous disease, and a skin biopsy was performed. The histopathologic specimen showed full-thickness sclerosis, with features of localized morphea. Therapy with clobetasol was prescribed, with progressive resolution of the thickness. The collaboration between many professionals in a multidisciplinary team (oncologist, dermatologist, plastic surgeon, and pathologist) was crucial to achieving the diagnosis. CONCLUSION In the literature, some articles describe correlation between connective tissue diseases and silicone breast implants, but the pathogenetic mechanisms are unknown. We report a rare case of breast morphea after positioning a silicone implant in a patient who had undergone mastectomy. This clinical report represents an interesting model of multidisciplinary management of a patient with breast cancer who developed an uncommon dermatologic disease. Further studies are needed to clarify the association between silicone implants and breast morphea.
Collapse
Affiliation(s)
- A Moretti
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| | - F Bianchi
- 2 Department of Pathology, ASST Fatebenefratelli & Sacco, Milan, Italy
| | - I V Abbate
- 3 Department of Dermatology, Umberto I Hospital Lugo, (Ravenna), Italy
| | - G Gherardi
- 2 Department of Pathology, ASST Fatebenefratelli & Sacco, Milan, Italy
| | - M Bonavita
- 4 Department of Plastic Surgery, Fatebenefratelli, ASST Fatebenefratelli & Sacco, Milan, Italy
| | - E Passoni
- 5 Department of Dermatology, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - G Nazzaro
- 6 Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Italy
| | - A Bramati
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| | - M C Dazzani
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| | - S Piva
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| | - E Paternò
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| | - N Frungillo
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| | - G Farina
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| | - N La Verde
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| |
Collapse
|
28
|
La Verde N, Collovà E, Blasi L, Pinotti G, Bernardo A, Bonotto M, Garrone O, Brunello A, Cavazzini MG, Bareggi C, Prochilo T, Porcu L, Moretti A, Barni S. Abstract P1-14-04: Overall survival in metastatic breast cancer patients in the third millennium: Results of an Italian study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-14-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND - Metastatic breast cancer (MBC) is a life-threatening disease. It is important to provide data about real-life MBC patients (pts) to understand the current prognostic factors. The aim of the present observational study, named COSMO (Checking Overall Survival in a MBC Observational study) is to describe the overall survival (OS) in a large cohort of MBC pts, assessing its correlation with specific prognostic factors (demographic, clinic, pathologic and biological).
PATIENTS AND METHODS - The COSMO study is a multicenter, retrospective, cohort study, developed throughout the collaboration of 31 Italian oncological centers. Data about pts diagnosed as metastatic from 01/01/2000 to 31/12/2008, were collected. The association between molecular subtypes, metastatic sites, disease free interval (DFI) and OS were assessed. Pts were classified in three subgroups, based on the biological characteristics of their tumor: luminal, HER2-positive (regardless of hormone receptor) and triple negative (TN). Metastatic sites were categorized as visceral versus non-visceral disease, only bone and central nervous system (CNS) metastases. DFI was calculated from diagnosis to first relapse only for M0 pts.
RESULTS - Of 3931 MBC pts enrolled in the study, 3720 were evaluable, with a median age of 61 years (interquartile range, IQR, 51-71). 1804 (62,1%) pts had a luminal disease, 691 (23,8%) HER2-positive, 410 (14.1%) TN. Median DFI was 3.2 years (IQR 1.7- 6.0). Regarding metastatic sites, pts with visceral disease were 2332 (63%); 826 (22,2%) pts had bone isolated metastases; in 306 (8,3%) pts, CNS metastases were reported. With a median follow up of 9 years (IQR 5.7-11.0) and 3098 (83.3%) recorded events, we founded a median OS of 2.8 years (95%CI: 2.7-2.9) years. OS was strictly depending from molecular subtypes with a better prognosis for HER2-positive versus luminal and TN MBC pts, median OS of 3.1 (95%CI 2.8-3.4), 3.0 (95%CI: 2.9-3.1) and 1.5 (95%CI: 1.3-1.7) years respectively (p-value<0.001). 525 (14,1%) pts received trastuzumab. Metastatic sites affect prognosis, with a better OS for bone disease (3.4 years, 95%CI: 3.1-3.6) versus visceral disease (2.2 years 95%CI: 2.0- 2.3). Brain metastasis correlate with the worst prognosis: OS of 1.5 years (95% CI: 0.8 – 1.7). Even DFI shows a correlation with prognosis: pts with DFI>2 years show a median OS of 3 years (95% CI: 2.9 – 3.2), while those with DFI<2 years have a median OS of 2.4 years (95% CI: 2.3-2.6); HR was 0.69 (95%CI: 0,62-0,76) for every five years of increase in DFI (p-value<0.001).
CONCLUSIONS - Molecular subtype is crucial for prognosis: HER2-positive subtype has the best prognosis, while TN subtype has the shorter OS. Having a longer DFI from diagnosis (>2 years) correlate with a better prognosis. Our study confirm that sites of metastasis affects outcome: visceral involvement correlates with poor prognosis and, particularly, pts with brain metastasis represent the worst subgroup, while pts with solely bone disease have the best prognosis. The COSMO study provides a view on the Italian landscape of MBC between 2000 and 2008, adding new insights about pts prognosis.
Citation Format: La Verde N, Collovà E, Blasi L, Pinotti G, Bernardo A, Bonotto M, Garrone O, Brunello A, Cavazzini MG, Bareggi C, Prochilo T, Porcu L, Moretti A, Barni S, On Behalf of COSMO Study Group. Overall survival in metastatic breast cancer patients in the third millennium: Results of an Italian study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-14-04.
Collapse
Affiliation(s)
- N La Verde
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - E Collovà
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - L Blasi
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - G Pinotti
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - A Bernardo
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - M Bonotto
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - O Garrone
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - A Brunello
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - MG Cavazzini
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - C Bareggi
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - T Prochilo
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - L Porcu
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - A Moretti
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - S Barni
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | | |
Collapse
|
29
|
Munkvold GP, Weieneth L, Proctor RH, Busman M, Blandino M, Susca A, Logrieco A, Moretti A. Pathogenicity of Fumonisin-producing and Nonproducing Strains of Aspergillus Species in Section Nigri to Maize Ears and Seedlings. Plant Dis 2018; 102:282-291. [PMID: 30673533 DOI: 10.1094/pdis-01-17-0103-re] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Species of Aspergillus section Nigri are commonly associated with maize kernels, and some strains can produce fumonisin mycotoxins. However, there is little information about the extent to which these fungi contribute to fumonisin contamination in grain, the damage they cause to maize ears, or their effects on maize seed germination and seedling health. We compared fumonisin-producing and nonproducing strains of A. niger, A. welwitschiae, A. phoenicis, A. tubingensis, and A. carbonarius from the United States and Italy in laboratory and field studies to assess their ability to contribute to fumonisin contamination, to cause maize ear rot, and to affect seed germination and seedling growth. In laboratory experiments, some strains of each Aspergillus species reduced germination or seedling growth, but there was high variability among strains within species. There were no consistent differences between fumonisin-producing and nonproducing strains. In field studies in Iowa and Illinois, strains were variable in their ability to cause ear rot symptoms, but this was independent of the ability of the Aspergillus strains to produce fumonisins. Contamination of grain with fumonisins was not consistently increased by inoculation with Aspergillus strains compared with the control, and was much greater in F. verticillioides-inoculated treatments than in Aspergillus-inoculated treatments. However, the ratio of the FB analogs FB2 and FB1 was altered by inoculation with some Aspergillus strains, indicating that FB2 production by Aspergillus strains occurred in the field. These results demonstrate the pathogenic capabilities of strains of Aspergillus in section Nigri, but suggest that their effects on maize ears and seedlings are not related to their ability to produce fumonisins, and that fumonisin contamination of grain caused by Aspergillus spp. is not as significant as that caused by Fusarium spp.
Collapse
Affiliation(s)
- G P Munkvold
- Iowa State University, Plant Pathology and Microbiology, Ames, IA
| | - L Weieneth
- Iowa State University, Plant Pathology and Microbiology, Ames, IA
| | - R H Proctor
- USDA-ARS, National Center for Agricultural Utilization Research, Peoria, IL
| | - M Busman
- USDA-ARS, National Center for Agricultural Utilization Research, Peoria, IL
| | | | | | | | | |
Collapse
|
30
|
Merla C, Andreoli G, Garino C, Vicari N, Tosi G, Guglielminetti ML, Moretti A, Biancardi A, Arlorio M, Fabbi M. Monitoring of ochratoxin A and ochratoxin-producing fungi in traditional salami manufactured in Northern Italy. Mycotoxin Res 2018; 34:107-116. [DOI: 10.1007/s12550-017-0305-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Revised: 11/29/2017] [Accepted: 12/25/2017] [Indexed: 10/18/2022]
|
31
|
Liguori S, de Sire A, Moretti A, Sodano L, Sampaolo S, Gimigliano F, Iolascon G. Musculoskeletal impairment and functional limitations in a patient affected by mutation in the laminin a-5 gene. Funct Neurol 2018. [PMID: 29984690 DOI: 10.11138/fneur/2018.33.2.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
32
|
Dreßen M, Northoff B, Laue S, Neb I, Zhang Z, Gödel A, Doppler S, Deutsch M, Lahm H, Teupser D, Moretti A, Laugwitz KL, Holdt L, Lange R, Krane M. Identification of Differentially Regulated Pathways in Cardiac Development and Cardiac Gene Expression during In Vitro Cardiac Differentiation of HLHS-derived Human Induced Pluripotent Stem Cells using Transcriptome Analysis. Thorac Cardiovasc Surg 2018. [DOI: 10.1055/s-0038-1628043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- M. Dreßen
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - B. Northoff
- Institute for Laboratory Medicine, University Hospital, Ludwig-Maximilian University Munich, Munich, Germany
| | - S. Laue
- First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - I. Neb
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - Z. Zhang
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - A. Gödel
- First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - S. Doppler
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - M. Deutsch
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - H. Lahm
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - D. Teupser
- Institute for Laboratory Medicine, University Hospital, Ludwig-Maximilian University Munich, Munich, Germany
| | - A. Moretti
- First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - K.-L. Laugwitz
- First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - L. Holdt
- Institute for Laboratory Medicine, University Hospital, Ludwig-Maximilian University Munich, Munich, Germany
| | - R. Lange
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - M. Krane
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| |
Collapse
|
33
|
Jozinovic A, Battilani P, Moretti A, Streit E, Sarkanj B, Pollak L, Zivancev D, Cacic Kenjeric D, Tisma M, Strelec I. Scientific Report of the 9th International Congress “Flour-Bread ’17”. Croat J Food Sci Technol 2017. [DOI: 10.17508/cjfst.2017.9.2.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
34
|
Migliaccio S, Francomano D, Romagnoli E, Marocco C, Fornari R, Resmini G, Buffa A, Di Pietro G, Corvaglia S, Gimigliano F, Moretti A, de Sire A, Malavolta N, Lenzi A, Greco EA, Iolascon G. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy. J Endocrinol Invest 2017; 40:1321-1326. [PMID: 28589380 DOI: 10.1007/s40618-017-0701-3] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/21/2017] [Accepted: 05/26/2017] [Indexed: 02/08/2023]
Abstract
BACKGROUND Persistence is commonly considered a key factor for the successful management of osteoporosis and fragility fractures. Denosumab is the first biologic agent developed for the treatment of osteoporosis with satisfying data regarding the persistence with this therapy. AIM The purpose of this multicenter observational real practice study was to evaluate the persistence with denosumab treatment in post-menopausal women affected by osteoporosis. MATERIAL/SUBJECTS AND METHODS Women were recruited in four specialized centers for the management of osteoporosis in North, Center and South of Italy. We included women with a diagnosis of post-menopausal osteoporosis, aged >50 years, able to obtain a prescription according to the Italian reimbursement criteria in force during the study period for anti-osteoporotic pharmacological treatment. They initiated a treatment with subcutaneous denosumab (Prolia®) 60 mg/every 6 months between November 2011 and May 2016. Women who had received aromatase inhibitors were excluded. Patients were assessed at baseline and every 6 months for all treatment length. Persistence data were evaluated for a total of 36 months. RESULTS Eight hundred seventy women were enrolled; mean aged 70 years, with a mean body mass index of 24.8 ± 4.1 kg/m2. At the Dual-energy X-ray absorptiometry assessment, the mean lumbar spine T-score was -2.76 ± 1.14 standard deviations (SD) and the mean femoral neck T-score was -2.49 ± 0.80 SD. During the study, the total persistence was 91.4%. Total dropouts were 75 (8.6%), higher within the initial 6-month period of treatment. CONCLUSIONS Persistence to denosumab treatment in our observational real practice study was very high. These results suggest that factors such as frequency of visits, pharmacological schedule, and opportunity to call the doctor might play an important role in the persistence and adherence to treatment to obtain maximum therapeutic effect and avoid further fragility fractures.
Collapse
Affiliation(s)
- S Migliaccio
- Section of Health Sciences, Department of Movement, Human and Health Sciences, University "Foro Italico", Piazza Lauro de Bosis, 6, 00135, Rome, Italy.
| | - D Francomano
- Section of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - E Romagnoli
- Section of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - C Marocco
- Section of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - R Fornari
- Section of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - G Resmini
- Section of Orthopaedic and Traumatology, Center of Osteoporosis and Skeletal Metabolic Diseases, ASST-Bergamo Ovest, Treviglio-Caravaggio, Italy
| | - A Buffa
- Departmental Program: Rheumatic, Connective and Bone Metabolic Diseases Management Bologna, Department of Medical and Surgical Sciences, St Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - G Di Pietro
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Via de Crecchio 4, 80138, Naples, Italy
| | - S Corvaglia
- Departmental Program: Rheumatic, Connective and Bone Metabolic Diseases Management Bologna, Department of Medical and Surgical Sciences, St Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - F Gimigliano
- Department of Physical and Mental Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - A Moretti
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Via de Crecchio 4, 80138, Naples, Italy
| | - A de Sire
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Via de Crecchio 4, 80138, Naples, Italy
| | - N Malavolta
- Departmental Program: Rheumatic, Connective and Bone Metabolic Diseases Management Bologna, Department of Medical and Surgical Sciences, St Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - A Lenzi
- Section of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - E A Greco
- Section of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - G Iolascon
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Via de Crecchio 4, 80138, Naples, Italy.
| |
Collapse
|
35
|
Caroli P, De Giorgi U, Scarpi E, Fantini L, Moretti A, Galassi R, Celli M, Conteduca V, Rossi L, Bianchi E, Paganelli G, Matteucci F. Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Eur J Nucl Med Mol Imaging 2017; 45:348-354. [PMID: 29110067 DOI: 10.1007/s00259-017-3866-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2017] [Accepted: 10/20/2017] [Indexed: 12/19/2022]
Abstract
PURPOSE The role of 18F-choline positron emission tomography/computed tomography (FCH-PET/CT) in patients with metastatic castration-resistant prostate cancer (mCRPC) has been firmly established in recent years. We analyzed the prognostic value of functional parameters such as mean standardized uptake volume (SUVmean), maximum standardized uptake volume (SUVmax), metabolic total volume (MTV; the volume of interest consisting of all spatially connected voxels within a fixed threshold of 40% of the SUVmax), and total lesion activity (TLA: the product of MTV and mean standardized uptake value) estimated with FCH-PET/CT in mCRPC patients in progression after docetaxel and treated with new antiandrogen receptor therapies, abiraterone or enzalutamide. METHODS We retrospectively studied 94 mCRPC patients, mean age 74 years (range 42-90), previously treated with docetaxel who were treated with either abiraterone (n = 52) or enzalutamide (n = 42). An FCH-PET/CT was performed at baseline, and patients were evaluated on a monthly basis for serological PSA response and every 3 months for radiological response. We measured MTV, SUVmean, SUVmax and TLA for each lesion and analyzed the sum of MTV (SMTV), SUVmean (SSUVmean), SUVmax (SSUVmax) and TLA (STLA) values for a maximum of 20 lesions. Univariate analysis was used to correlate these data with PFS and OS. RESULTS We observed a median SMTV of 130 cm3, median SSUVmax of 106.5 and a median STLA of 495,070. All of these parameters were significant for PFS and OS in univariate analysis, while only STLA was significant for PFS and OS in multivariate analysis after adjusting for lesion and age (p < 0.0001 and p = 0.001, respectively). Baseline PSA values maintained a certain reliability for OS (p = 0.034). CONCLUSIONS Semiquantitative parameters of FCH-PET/CT play a prognostic role in mCRCP patients treated with abiraterone or enzalutamide.
Collapse
Affiliation(s)
- Paola Caroli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
| | - Ugo De Giorgi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Emanuela Scarpi
- Unit of Biostatistics and Clinical Trials Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Lorenzo Fantini
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Andrea Moretti
- Nuclear Medicine Unit, Morgagni Pierantoni Hospital, Forlì, Italy
| | - Riccardo Galassi
- Nuclear Medicine Unit, Morgagni Pierantoni Hospital, Forlì, Italy
| | - Monica Celli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Vincenza Conteduca
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Lorena Rossi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | | | - Giovanni Paganelli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Federica Matteucci
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| |
Collapse
|
36
|
Iolascon G, Gimigliano F, Moretti A, de Sire A, Migliore A, Brandi M, Piscitelli P. Early osteoarthritis: How to define, diagnose, and manage. A systematic review. Eur Geriatr Med 2017. [DOI: 10.1016/j.eurger.2017.07.008] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
37
|
Martella L, Daniel F, Moretti A, Toma I, Lancia F, Tiberi E, Mauro E, Schirone A, Santini A, Frassoldati A. Scalp cooling: a real opportunity to prevent alopecia in breast cancer women undergoing chemotherapy? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Daniel F, Bannò E, Belluomini L, Martella L, Lancia F, Toma I, Moretti A, Mentrasti G, Carandina I, Marzola M, Frassoldati A. The regorafenib issue: focus on efficacy and safety in pre-treated metastatic colorectal cancer from a real world experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
39
|
Belluomini L, Fiorica F, Stefanelli A, Santini A, Urbini B, Daniel F, Martella L, Toma I, Lancia F, Moretti A, Bannò E, Giorgi C, Frassoldati A. Efficacy and safety of immune checkpoint inhibitor nivolumab and radiotherapy combination in advanced NSCLC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Toma I, Lancia F, Scapoli D, Frassoldati A, Panareo S, Santi I, Cittanti C, Bartolomei M, Daniel F, Moretti A, Martella L, Belluomini L, Mentrasti G. Bone pain control in Castration resistant prostate cancer (CRPC): retrospective analysis of first patients trated with Radium 223. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx423.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Moretti A, Lupini L, Carandina I, Bassi C, Martella L, Lancia F, Daniel F, Belluomini L, Toma I, Bannò E, Nisi C, Da Ros L, Querzoli P, Negrini M, Frassoldati A. Estrogen receptor mutation: a new strategy to overcome endocrine resistance. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Carandina I, Belluomini L, Bonetti F, Urbini B, Daniel F, Lancia F, Martella L, Toma I, Moretti A, Bannò E, Nisi C, Da Ros L, Frassoldati A. Efficacy of anti-EGFR antibodies combined with chemotherapy for elderly patients with RAS wild-type metastatic colorectal cancer: a systematic review and metanalysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
43
|
Belluomini L, Carandina I, Bonetti F, Urbini B, Daniel F, Lancia F, Martella L, Toma I, Moretti A, Bannò E, Nisi C, Da Ros L, Frassoldati A. Efficacy of anti-EGFR antibodies combined with chemotherapy for elderly patients with RAS wild-type metastatic colorectal cancer: A systematic review and metanalysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Matteucci F, Mezzenga E, Caroli P, Di Iorio V, Sarnelli A, Celli M, Fantini L, Moretti A, Galassi R, De Giorgi U, Paganelli G. Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results. Eur J Nucl Med Mol Imaging 2017; 44:2189-2194. [PMID: 28801787 DOI: 10.1007/s00259-017-3791-4] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Accepted: 07/24/2017] [Indexed: 11/30/2022]
Abstract
PURPOSE Urea-based prostate-specific membrane antigen (PSMA) ligands labelled with 68Ga or 177Lu are new tracers with great potential for theranostic approaches in prostate cancer. However, clinical studies have shown that the kidneys are one of the off-target organs along with the salivary and lacrimal glands. In the kidneys, PSMA is physiologically expressed in the apical epithelium of the proximal tubules, and mannitol acts as an osmotic diuretic in these tubules. We investigated the potential of mannitol to reduce renal uptake of 68Ga-PSMA. METHODS Kidney uptake (SUVmax) was calculated in nine patients undergoing 68Ga-PSMA PET/CT at baseline (b-PET/CT) and after intravenous infusion of 500 ml of 10% mannitol (m-PET/CT). Two different infusion schemes for mannitol were used: (1) 500 ml mannitol was infused over 40 min after 68Ga-PSMA administration (A-infusion) and (2) 250 ml mannitol was infused over 15 min before and again after 68Ga-PSMA administration (B-infusion). RESULTS In patients receiving the A-infusion, mean SUVmax increased by 11.9% and 7.4% in the right and left kidney, respectively. In patients receiving the B-infusion, mean SUVmax decreased by 24.3% and 22.4% in the right and left kidney, respectively. CONCLUSION Our preliminary findings indicate that mannitol may play a role in reducing off-target 68Ga-PSMA renal uptake. Administration of the osmotic diuretic should be rapid and start before 68Ga-PSMA injection. These results warrant dosimetric studies in patients treated with 177Lu-PSMA to find the best scheme for mannitol administration.
Collapse
Affiliation(s)
- Federica Matteucci
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Emilio Mezzenga
- Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Paola Caroli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Valentina Di Iorio
- Oncology Pharmacy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Anna Sarnelli
- Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Monica Celli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Lorenzo Fantini
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | | | | | - Ugo De Giorgi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
| | - Giovanni Paganelli
- Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
| |
Collapse
|
45
|
Schick R, Mekies L, Shemer Y, Hallas T, Ben-Ari M, Gherghiceanu M, Simona Pane L, My I, Freimark D, Arad M, Moretti A, Binah O. P3496Functional abnormalities in induced pluripotent stem cell-derived cardiomyocytes generated from titin-mutated dilated cardiomyopathy patients. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
46
|
Sinnecker D, Chen Z, Goedel A, My I, Dreizehnter L, Moretti A, Laugwitz KL. P2561All-optical imaging of membrane potential and calcium signalling in patient-specific hiPSC-derived cardiomyocytes. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Pannarale G, Torromeo C, Acconcia MC, Moretti A, De Angelis V, Tanzilli A, Paravati V, Barillà F, Gaudio C. Two cases of acute chest discomfort and the Central Italy earthquake. Oxf Med Case Reports 2017; 2017:omx005. [PMID: 29744121 PMCID: PMC5934663 DOI: 10.1093/omcr/omx005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2016] [Revised: 01/18/2017] [Accepted: 02/16/2017] [Indexed: 11/18/2022] Open
Abstract
We present the cases of two postmenopausal women presenting to our emergency department with acute chest discomfort soon after the Central Italy earthquake. Different diagnoses were made in the two patients. The role of the earthquake as a stressful event triggering diverse chest pain syndromes is discussed.
Collapse
Affiliation(s)
- Giuseppe Pannarale
- Dipartimento Cuore e Grossi Vasi, Sapienza Università di Roma, Rome, Italy
| | - Concetta Torromeo
- Dipartimento Cuore e Grossi Vasi, Sapienza Università di Roma, Rome, Italy
| | | | - Andrea Moretti
- Dipartimento Cuore e Grossi Vasi, Sapienza Università di Roma, Rome, Italy
| | | | | | - Vincenzo Paravati
- Dipartimento Cuore e Grossi Vasi, Sapienza Università di Roma, Rome, Italy
| | - Francesco Barillà
- Dipartimento Cuore e Grossi Vasi, Sapienza Università di Roma, Rome, Italy
| | - Carlo Gaudio
- Dipartimento Cuore e Grossi Vasi, Sapienza Università di Roma, Rome, Italy
| |
Collapse
|
48
|
Festa V, Spila Alegiani S, Chiesara F, Moretti A, Bianchi M, Dezi A, Traversa G, Koch M. Retrospective comparison of long-term ten-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2017; 21:1397-1404. [PMID: 28387885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE Diverticular disease (DD) of the colon has an increasing burden on health services. The effectiveness of rifaximin for the treatment of DD, is not yet established. The aim of this study is to assess the impact of long-term treatment with rifaximin or mesalazine in a 10-day schedule for the prevention of recurrent diverticulitis. PATIENTS AND METHODS This is a retrospective study. We identified all consecutive patients with DD and previous acute diverticulitis (AD) in our outpatients' database; 124 patients, were included. The recommended therapy consisted of a ten-day/month treatment with either rifaximin (400 mg bid), or mesalazine (2.4 g/daily). Primary end point was AD recurrence. RESULTS Between 2010 and 2014, 72 patients were treated with rifaximin and 52 with mesalazine. During a median follow-up of 15 months (range 1-50), we observed 21 episodes of AD among users of either rifaximin (n=7; 0.54 per 100 person-months), or mesalazine group (n=14; 1.46 per 100 person-months). Kaplan-Meier survival estimates of recurrent AD significantly differed between rifaximin and mesalazine groups (p=0.015). The multivariate Cox regression analysis showed that AD recurrence was significantly associated with therapy (rifaximin vs. mesalazine, adjusted HR 0.27; 95% CI: 0.10 to 0.72), age and gender. CONCLUSIONS Long-term treatment with rifaximin in a 10-day schedule appears more effective than mesalazine in preventing recurrent AD.
Collapse
Affiliation(s)
- V Festa
- Gastroenterology and Liver Unit, S. Filippo Neri General Hospital, Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
49
|
La Verde N, Moretti A, Damia G, Paternò E, Santini D, Garrone O, Fabi A, Ciccarese M, Cretella E, Torri V, Generali D, Grasso D, Puglisi F, Collovà E, Roila F, Bertolini A, Barni S, Vici P, Luigi C, Scandurra G, Bramati A, Dazzani MC, Farina G. Abstract OT1-01-05: PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot1-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND Eribulin is a synthetic analogue of halichondrin B which inhibits microtubule dynamics. It has been approved in Europe for the treatment of locally advanced or metastatic breast cancer (mBC) progressed after at least two chemotherapy regimens for advanced disease. The most common adverse events (AEs) were fatigue, neutropenia and peripheral neuropathy, which occurs with an incidence ranging from 13.9% to 35%. It was severe only in a small proportion of patients, suggesting an individual susceptibility. The neurotoxicity mechanisms associated with microtubulin interfering agents have not been fully defined. Few studies reported an association between some SNPs (Single Nucleotide Polymorphisms) and microtubulin interfering agents-induced neuropathy, mainly taxanes. As the use of Eribulin becomes more widespread, a better knowledge of its safety profile, outside of clinical trials, is warranted. Given that Eribulin toxicity can result in treatment discontinuation, the ability to anticipate which patients will experience severe toxicity could allow for either early intervention or even possibly for prophylactic therapy, or for a better selection of patients eligible for treatment.
METHODS This is a multicenter, interventional, single-arm, phase IV study. The primary objective is the evaluation of the safety and tolerability profile of Eribulin in an unselected population of patients with mBC. Secondary objectives are the description of compliance to treatment and efficacy.
ENDPOINTS
•Incidence, time of onset, severity and duration of all AEs experienced during treatment with Eribulin, especially the most common reported in previous studies but also other possible unexpected toxicities.
•Association between a set of selected SNPs and the onset of any grade peripheral neuropathy. Specifically, 15 SNPs located in genes involved in microtubule dynamics or resulted from genome wide association studies, will be analyzed.
•Evaluation of quality of life during treatment using validated questionnaires.
•Assessment of dose intensity and dose schedule maintenance.
•DOT (Duration Of Treatment) and OS (Overall Survival).
STATISTICAL METHODS Summary statistics will be used in order to describe patient characteristics. Safety endpoints will be estimated by means of absolute and relative frequencies and associated 95%CI. The relationship between baseline variables and the risk of severe toxicity, as well as the relationship between SNPs and risk of neuropathy will be described by means of contingency tables and their association with outcome will be assessed by χ2 test of Mantel-Haenzel and a logistic regression model. DOT and OS will be described using Kaplan-Meier curves. A sample size of 200 patients will also allow us to get a good fitting for statistical analysis of the relationship between primary endpoint and not more than 10 factors. Regarding the relationship between SNPs and risk of neuropathy it will be feasible to screen for association about 10-15 SNPs, with known prevalence >15%.
PRESENT ACCRUAL AND TARGET ACCRUAL 98 of 200 patients were enrolled until 18/05/2016. Target accrual is open for 200 patients.
CONTACT INFORMATION Nicla La Verde: nicla.laverde@asst-fbf-sacco.it.
Citation Format: La Verde N, Moretti A, Damia G, Paternò E, Santini D, Garrone O, Fabi A, Ciccarese M, Cretella E, Torri V, Generali D, Grasso D, Puglisi F, Collovà E, Roila F, Bertolini A, Barni S, Vici P, Luigi C, Scandurra G, Bramati A, Dazzani MC, Farina G. PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT1-01-05.
Collapse
Affiliation(s)
- N La Verde
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - A Moretti
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - G Damia
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - E Paternò
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - D Santini
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - O Garrone
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - A Fabi
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - M Ciccarese
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - E Cretella
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - V Torri
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - D Generali
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - D Grasso
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - F Puglisi
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - E Collovà
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - F Roila
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - A Bertolini
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - S Barni
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - P Vici
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - C Luigi
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - G Scandurra
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - A Bramati
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - MC Dazzani
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - G Farina
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| |
Collapse
|
50
|
Marenzoni ML, Morganti G, Moretta I, Crotti S, Agnetti F, Moretti A, Pitzurra L, Casagrande Proietti P, Sechi P, Cenci-Goga B, Franciosini MP. Microbiological and parasitological survey of zoonotic agents in apparently healthy feral pigeons. Pol J Vet Sci 2017; 19:309-15. [PMID: 27487504 DOI: 10.1515/pjvs-2016-0038] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Microbiological and parasitological investigation was carried out on a colony of feral pigeons, located in a green area near the main hospital of a Central Italy city. One hundred pigeons were submitted to clinical examination. Cloacal swabs, grouped in pool of 4 samples, were analyzed to detect the presence of Coxiella burnetii, Chlamydia psittaci, Chlamydophila spp. using a biomolecular procedure, while individual cloacal samples were examined for Salmonella spp., Campylobacter spp., and yeasts by means of a specific culture media. An ELISA test was used to determine the presence of Giardia spp., and Cryptosporidium spp. coproantigens. Individual serological samples were also tested with the modified agglutination test (MAT) in order to detect antibodies against Toxoplasma gondii. The pigeons did not show any clinical signs. The cloacal pools proved to be negative for C. burnetii DNA while three pools were positive for C. psittaci or Chlamydophila spp. DNAs. Salmonella spp. was not detected. C. jejuni and C. coli were found in 13% and 4% of the samples, respectively. No Giardia spp. and Cryptosporidium spp. were detected. Thirty-three out of 100 samples (33%) were positive for yeast colonies. The seroprevalence for T. gondii was 8%. Although with moderate incidence, potentially zoonotic agents were present thus highlighting the need for sanitary surveillance on feral pigeon colonies.
Collapse
|